Combination therapy with targeting 4-1BB (CD137) agonists

By combining 4-1BBL trimer antigen binding molecules with HER-2 targeting agents, targeting tumor-associated antigens, the inadequacy of HER-2 targeting therapy for low-expression cancers and the risk of toxicity of 4-1BB agonist is solved. The problem has achieved more efficient and safer tumor treatment effects.

CN119074931APending Publication Date: 2024-12-06F HOFFMANN LA ROCHE & CO AG
View PDF 0 Cites 0 Cited by

Patent Information

Application Number
CN202411106242.9
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Priority Date
2018-03-13
Filing Date
2019-03-12
Publication Date
2024-12-06

AI Technical Summary

Technical Problem

The existing HER-2 targeted therapies are effective in some patients but have resistance problems, especially in cancers expressing low levels of HER2, and there is a risk of toxicity in clinical applications of 4-1BB agonists, which is difficult to Safe and effective activation of T cells.

Method used

Using antigen-binding molecules containing 4-1BBL trimer combined with HER-2 targeting agents, reduce binding to Fc receptors, reduce nonspecific cross-linking, and improve 4-1BB agonist by targeting tumor-related antigens such as FAP. safety and effectiveness.

Benefits of technology

This combination therapy is more effective in inhibiting tumor growth and eliminating tumor cells than using 4-1BB agonist or HER-2 targeted therapy alone, reducing the risk of hepatotoxicity and improving the safety and efficacy of the treatment.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure BDA0004990901090000251
    Figure BDA0004990901090000251
  • Figure BDA0004990901090000681
    Figure BDA0004990901090000681
  • Figure BDA0004990901090000691
    Figure BDA0004990901090000691
Patent Text Reader

Abstract

The present application relates to combination therapies employing a 4-1BB (CD137) agonist, in particular an antigen binding molecule comprising a 4-1BBL trimer, in combination with a HER-2 targeting agent, the use of these combination therapies for the treatment of cancer, and methods of using the combination therapies.
Need to check novelty before this filing date? Find Prior Art

Description

[0001] This application is a divisional application of the invention application with the application date of March 12, 2019, the Chinese application number of 201980009783.0, and the invention name of “Combination therapy with targeted 4-1BB (CD137) agonists”. Technical Field

[0002] The present invention relates to a combination therapy using a 4-1BB (CD137) agonist (particularly an antigen binding molecule containing a 4-1BBL trimer) and a HER-2 targeting agent, and uses of the combination therapy for treating cancer and methods of using the combination therapy. Background Art

[0003] Cancer is one of the leading causes of death worldwide. Despite advances in treatment options, the prognosis for patients with advanced cancer remains poor. Therefore, there is a lasting and urgent medical need for optimal treatments that extend the survival of cancer patients without causing unacceptable toxicity. Recent results from clinical trials have shown that immunotherapy can extend the overall survival of cancer patients and induce a lasting response. Despite these promising results, current immune-based therapies are only effective in a subset of patients, and combined strategies are needed to improve therapeutic benefit.

[0004] Human epidermal growth factor receptor-2 (HER-2; ErbB2) is a member of the epidermal growth factor receptor (EGFR) family of receptor tyrosine kinases and transmembrane receptors. HER-2 is overexpressed in a range of tumor types and is involved in disease initiation and progression. It is associated with a poor prognosis. For example, overexpression of HER-2 is observed in approximately 30% of human breast cancers and is associated with aggressive growth and poor clinical outcomes associated with these tumors (Slamon et al. (1987) Science 235: 177-182).

[0005] Humanized anti-HER-2 monoclonal antibody trastuzumab (CAS180288-69-1, huMAb4D5-8, rhuMAb HER2, Genentech) targets the extracellular domain of HER-2 ( US 5677171 ; US 5821337 ; US 6054297 ; US 6165464 ; US 6339142 ; US 6407213 ; US 6639055 ; US 6719971 ; US 6800738 ; US7074404 ; Coussens et al. (1985) Science 230:1132-9 ; Slamon et al. (1989) Science 244:707-12 ; Slamon et al. (2001) New Engl J Med 344:783-792 ). Trastuzumab has been shown to inhibit the proliferation of human tumor cells that overexpress HER-2 and is a mediator of antibody-dependent cellular cytotoxicity (ADCC) (Hudziak et al. (1989) Mol Cell Biol 9:1165-72; Lewis et al. (1993) Cancer Immunol Immunother 37:255-63; Baselga et al. (1998) Cancer Res 58:2825-2831; Hotaling et al. (1996) [Abstract] Proc Annual Meeting Am Assoc Cancer Res 37:471; Pegram MD et al. (1997) [Abstract] Proc Am Assoc Cancer Res 38:602; Sliwkowski et al. (1999) Seminars in Oncology 26(4), Suppl 12:60-70; Yarden Y. and Sliwkowski, M. (2001) Nature Reviews: Molecular Cell Biology, Macmillan Magazines, Ltd., Vol. 2: 127-137).

[0006] (Trastuzumab, Genentech Inc.) was approved in 1998 for the treatment of patients with HER2-overexpressing metastatic breast cancer (Baselga et al. (1996) J Clin Oncol 14:737-744). In 2006, the FDA approved As part of a treatment regimen containing doxorubicin, cyclophosphamide, and paclitaxel for the adjuvant treatment of patients with HER2-positive, node-positive breast cancer.

[0007] Trastuzumab-MCC-DM1 (T-DM1, trastuzumab emtansine, ado-trastuzumab emtansine, ), a novel antibody-drug conjugate (ADC) for the treatment of HER2-positive breast cancer, consists of the cytotoxic agent DM1 (a thiol-containing maytansinoid antimicrotubule agent) conjugated to trastuzumab at the lysine side chain via an MCC linker, with an average drug loading (drug to antibody ratio) of approximately 3.5. After binding to HER2 expressed on tumor cells, T-DM1 undergoes receptor-mediated internalization, leading to the intracellular release of cytotoxic catabolites containing DM1 and subsequent cell death. The FDA approved the drug in 2013 under the trademark Ado-trastuzumab emtansine is marketed for the treatment of patients with HER2-positive, metastatic breast cancer who have previously received treatment with trastuzumab and a taxane.

[0008] Pertuzumab (also known as recombinant humanized monoclonal antibody 2C4, rhuMAb 2C4, Genentech, Inc., South San Francisco) is another antibody therapy targeting HER-2. Pertuzumab is a HER dimerization inhibitor (HDI) and functions to inhibit the ability of HER2 to form active heterodimers or homodimers with other HER receptors (such as EGFR / HER1, HER2, HER3 and HER4). See, for example, Harari and Yarden, Oncogene 19:6102-14 (2000); Yarden and Sliwkowski, Nat Rev Mol Cell Biol 2:127-37 (2001); Sliwkowski, Nat Struct Biol 10:158-9 (2003); Cho et al., Nature 421:756-60 (2003); and Malik et al., Pro Am Soc Cancer Res 44:176-7 (2003); US 7560111. First approved in 2012 in combination with trastuzumab and docetaxel for the treatment of patients with advanced or advanced (metastatic) HER2-positive breast cancer. Combination therapy using trastuzumab and pertuzumab is also approved for neoadjuvant (before surgery) treatment of HER2-positive, locally advanced, inflammatory, or early breast cancer and for adjuvant (after surgery) treatment of HER2-positive early breast cancer (EBC) at high risk of recurrence. It is believed that the mechanisms of action of Perjeta and Herceptin complement each other because both bind to the HER2 receptor but to different locations. It is believed that the combination of Perjeta and Herceptin provides a more comprehensive dual blockade of the HER signaling pathway, thus preventing tumor cell growth and survival.

[0009] Bispecific, bivalent HER-2 antibodies directed against domains II, III and IV of human ErbB2 are disclosed in WO 2012 / 143523. A bispecific HER-2 antibody called Herceptarg comprising optimized variants of antibodies rhuMab 2C4 and hu4D5 is described in WO 2015 / 091738.

[0010] Although the therapeutic efficacy of trastuzumab in breast cancer is well documented, there are many patients who do not benefit from trastuzumab due to resistance. Given the lack of effective anti-HER2 therapies in certain cancers that express low levels of HER2, resistance to current therapies, and the prevalence of HER-2-associated cancers, new therapies are needed to treat such cancers.

[0011] A member of the TNF receptor superfamily, 4-1BB (CD137) was initially identified as an inducible molecule expressed by activated T cells (Kwon and Weissman, 1989, Proc Natl Acad Sci USA 86, 1963-1967). Subsequent studies have shown that many other immune cells also express 4-1BB, including NK cells, B cells, NKT cells, monocytes, neutrophils, mast cells, dendritic cells (DC) and cells of non-hematopoietic origin, such as endothelial and smooth muscle cells (Vinay and Kwon, 2011, Cell Mol Immunol 8, 281-284). The expression of 4-1BB in different cell types is mostly induced and driven by various stimulatory signals, such as T cell receptor (TCR) or B cell receptor triggering, as well as signaling induced by receptors of co-stimulatory molecules or proinflammatory cytokines (Diehl et al., 2002, J Immunol 168, 3755-3762; Zhang et al., 2010, Clin Cancer Res 13, 2758-2767).

[0012] 4-1BB ligand (4-1BBL or CD137L) was identified in 1993 (Goodwin et al., 1993, Eur J Immunol 23, 2631-2641). It has been shown that the expression of 4-1BBL is confined to professional antigen presenting cells (APC), such as B cells, DCs and macrophages. The inducible expression of 4-1BBL is characteristic for T cells including both αβ and γδ T cell subsets, and endothelial cells (Shao and Schwarz, 2011, J Leukoc Biol 89, 21-29).

[0013] Activation of T cells (CD4 + and CD8 + Subsets (two), a variety of signal transduction cascades within, strongly promote T cell activation (Bartkowiak and Curran, 2015). Combined with TCR triggering, agonist 4-1BB specific antibodies enhance the proliferation of T cells, stimulate lymphokine secretion and reduce the sensitivity of T lymphocytes to activation-induced cell death (Snell et al., 2011, Immunol Rev 244, 197-217). This mechanism is further developed as the first proof of concept in cancer immunotherapy. In a preclinical model, the administration of agonist antibodies for 4-1BB in tumor-bearing mice leads to a powerful anti-tumor effect (Melero et al., 1997, Nat Med 3, 682-685). Later, more and more evidence indicates that 4-1BB is usually only used with other immunomodulatory compounds, chemotherapeutic agents, tumor-specific vaccination or radiotherapy combined administration to show its effectiveness as an anti-tumor agent (Bartkowiak and Curran, 2015, Front Oncol 5, 117).

[0014] Signaling of the TNFR superfamily requires cross-linking of trimeric ligands to engage the receptor, and thus requires wild-type Fc-bound 4-1BB agonistic antibodies as well (Li and Ravetch, 2011, Science 333, 1030-1034). However, systemic administration of 4-1BB-specific agonistic antibodies with functionally active Fc domains in mice resulted in CD8+-associated hepatotoxicity. +The influx of T cells (Dubrot et al., 2010, Cancer Immunol Immunother 59, 1223-1233), which weakens or significantly alleviates under the absence of functional Fc receptors. In the clinic, a kind of Fc competent 4-1BB agonist antibody (BMS-663513) (NCT00612664) causes grade 4 hepatitis, resulting in termination of the trial (Simeone and Ascierto, 2012, JImmunotoxicol 9, 241-247). Therefore, it is necessary to have an effective and safer 4-1BB agonist.

[0015] A fusion protein consisting of an extracellular domain of a 4-1BB ligand and a single-chain antibody fragment (Hornig et al., 2012, J Immunother 35, 418-429; Müller et al., 2008, J Immunother 31, 714-722) or a single 4-1BB ligand fused to the C-terminus of the heavy chain (Zhang et al., 2007, Clin Cancer Res 13, 2758-2767) has been generated. WO 2010 / 010051 discloses the generation of a fusion protein consisting of three TNF ligand extracellular domains connected to each other and fused to an antibody portion. In the present invention, the antigen binding molecules consisting of trimerized and thus biologically active 4-1BB ligands and antigen binding domains specific for tumor-associated antigens and Fc inactive domains are shown to be particularly stable and robust. For tumor-specific co-stimulation via 4-1BB (CD137), a molecule comprising an antigen binding domain targeting FAP in the tumor stroma and a trimer of 4-1BB ligands is shown to be particularly useful, hereinafter referred to as FAP-4-1BBL. Through FAP-targeted specific cross-linking, the FAP antigen binding domain replaces the nonspecific FcγR-mediated cross-linking responsible for Fc-mediated toxicity (especially in the liver), thus reducing the risk of toxicity.

[0016] We describe herein a novel combination therapy for HER-2 expressing tumors. Summary of the invention

[0017] The present invention relates to 4-1BB (CD137) agonists, particularly antigen binding molecules containing 4-1BBL trimers, and their use in combination with HER-2 targeted therapy, particularly their use in a method for treating cancer or delaying cancer progression. It has been found that the combination therapy described herein is more effective in inhibiting tumor growth and eliminating tumor cells than the treatment with the 4-1BB agonist or known HER-2 targeted therapy alone.

[0018] In some aspects, the present invention provides a 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.

[0019] In some aspects, the HER-2 targeting agent comprises a HER-2 antibody, a bispecific HER-2 antibody and / or a HER-2 antibody drug conjugate. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and margetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0020] In some aspects, the 4-1BB agonist comprises three 4-1BBL outer domains or fragments thereof. In some aspects, the 4-1BB agonist is a molecule comprising three 4-1BBL outer domains or fragments thereof and wherein the 4-1BBL outer domain comprises an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, particularly SEQ ID NO: 1 or SEQ ID NO: 5 amino acid sequence.

[0021] In some other aspects, the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain that can specifically bind to tumor-associated antigens. In some aspects, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or its fragment and at least one antigen binding domain that can specifically bind to tumor-associated antigens. In one aspect, the tumor-associated antigen is selected from the group consisting of fibroblast activation protein (FAP) and CEA.

[0022] In some other aspects, the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain. In some aspects, the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector functions. In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising a modified Fc domain that reduces Fcγ receptor binding and / or effector function. It is possible to avoid nonspecific FcγR-mediated cross-linking and so can be applied with a higher and more effective dose of the 4-1BB agonist compared to a commonly used 4-1BB antibody.

[0023] In some aspects, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to fibroblast activation protein (FAP). In some aspects, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to FAP, wherein the antigen binding domain capable of specific binding to FAP comprises

[0024] (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or

[0025] (b) Heavy chain variable region (V H FAP and light chain variable region (V LFAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0026] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).

[0027] In some aspects, the 4-1BB agonist is an antigen binding molecule comprising:

[0028] (a) at least one antigen binding domain that is capable of specifically binding to FAP, and

[0029] (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the first polypeptide comprises two 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker and the second polypeptide comprises a 4-1BBL outer domain or a fragment thereof. In some aspects, the 4-1BB agonist is an antigen binding molecule comprising the following: (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprises a heavy chain variable region (V L ... H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 HFAP) and a light chain variable region (V L ... L FAP), and (b) a first and a second polypeptide linked to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and in that the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0030] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 41, a first light chain comprising the amino acid sequence of SEQ ID NO: 42, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44.

[0031] In some aspects, the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0032] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to CEA. In some aspects, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to CEA, wherein the antigen binding domain capable of specific binding to CEA comprises (a) heavy chain variable region (V H CEA and light chain variable region (V L CEA), the heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, the light chain variable region (V LCEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0033] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0034] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0035] (a) at least one antigen binding domain capable of specifically binding to CEA, and

[0036] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0037] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0038] In some aspects, the 4-1BB agonist is an antigen binding molecule comprising:

[0039] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0040] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0041] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0042] In yet another aspect, the 4-1BB agonist is an anti-CEA / anti-4-1BB bispecific antibody.

[0043] In other aspects, the 4-1BB agonist and the HER-2 targeting agent are used together in a single composition or separately in two or more different compositions. In some other aspects, the 4-1BB agonist and the HER-2 targeting agent act synergistically. In other aspects, the 4-1BB agonist and the HER-2 targeting agent are used in parallel, before the HER-2 targeting agent, or after the HER-2 targeting agent.

[0044] In some other aspects, provided is a combination comprising a 4-1BB agonist and a HER-2 targeting agent. In one aspect, the combination is for use as a drug, wherein the 4-1BB agonist and the HER-2 targeting agent are for simultaneous administration. In other aspects, the combination is for use as a drug, wherein the 4-1BB agonist and the HER-2 targeting agent are for sequential administration.

[0045] In another aspect, there is provided a pharmaceutical product comprising (A) a first composition comprising a 4-1BB agonist as an active ingredient and a pharmaceutically acceptable carrier; and (B) a second composition comprising a HER-2 targeting agent as an active ingredient and a pharmaceutically acceptable carrier, for use in combination, sequentially or simultaneously, in the treatment of a disease, particularly cancer.

[0046] In yet another aspect, there is provided a pharmaceutical composition comprising a 4-1BB agonist and a HER-2 targeting agent. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent is a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In yet other aspects, there is provided a pharmaceutical composition for use in treating cancer or delaying cancer progression, particularly treating advanced and / or metastatic solid tumors.

[0047] In yet another aspect, the present invention relates to the combination of a 4-1BB agonist and a HER-2 targeting agent in the manufacture of a drug for treating a proliferative disease, particularly a cancer or delayed proliferative disease, particularly a cancer progression. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent is a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine.

[0048] In another aspect, the present invention provides a method for treating cancer or delaying cancer progression in a subject, comprising administering an effective amount of a 4-1BB agonist and an effective amount of a HER-2 targeting agent to the subject. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent is a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine.

[0049] In some aspects, the present invention relates to a method for treating cancer or delaying cancer progression in a subject, comprising administering an effective amount of a 4-1BB agonist and an effective amount of a HER-2 targeting agent to the subject, wherein the 4-1BB agonist comprises three 4-1BBL outer domains or fragments thereof. In some aspects, the 4-1BB agonist is any 4-1BB agonist provided herein. In some aspects, the 4-1BB agonist and the HER-2 targeting agent are administered together in a single composition or separately in two or more different compositions. In some aspects, the 4-1BB agonist and the HER-2 targeting agent are administered intravenously or subcutaneously. In some aspects, the 4-1BB agonist is administered in parallel with the HER-2 targeting agent, before the HER-2 targeting agent, or after the HER-2 targeting agent.

[0050] In yet other aspects, the present invention relates to a 4-1BB agonist in combination with a HER-2 targeting agent or a pharmaceutical composition for use in treating cancer or delaying cancer progression, a combination of a 4-1BB agonist and a HER-2 targeting agent in the manufacture of a medicament for treating a proliferative disease, particularly cancer or delaying a proliferative disease, particularly cancer progression, or a method for treating cancer or delaying cancer progression in a subject, wherein the cancer is a HER-2 positive cancer. In some aspects, the cancer is breast cancer, ovarian cancer, gastric cancer, gastric cancer, esophageal cancer, lung cancer, uterine cancer, salivary duct cancer, bladder cancer, endometrial cancer, pancreatic cancer, colon cancer, prostate cancer, and / or head and neck cancer. BRIEF DESCRIPTION OF THE DRAWINGS

[0051] Figure 1A-Figure 1D Specific FAP-4-1BBL antigen binding molecules are shown. These molecules are described in more detail in Example 1. Dark black dots represent knob-into-hole modifications. Figure 1A The monovalent FAP antigen-binding molecule containing 4-1BBL trimer with modifications in the CH1 and CL domains adjacent to the 4-1BBL dimer and 4-1BBL monomer is shown. Because it contains the FAP binder 4B9, it is named mono FAP (4B9)-4-1BBL herein. Figure 1B A bivalent construct with the binder FAP(4B9), termed bi FAP(4B9)-4-1BBL, is shown. Figure 1C and Figure 1D A non-targeting control molecule is shown (the FAP binder has been replaced with a non-binding DP47 Fab).

[0052] Figure 2A and Figure 2B Simultaneous binding of the hybrid surrogate FAP-mu4-1BBL (Analyte 1) to immobilized murine 4-1BB and human FAP or murine FAP (Analyte 2) is shown, respectively. Figure 2C Simultaneous binding of the murine bispecific FAP-4-1BB antibody muFAP-4-1BB (Analyte 1) to immobilized murine 4-1BB and murine FAP (Analyte 2) is shown in FIG.

[0053] Figure 3 The pharmacokinetic profile of muFAP-4-1BB after a single injection in C57BL / 6 mice is shown as described in Example 4. A stable PK behavior was observed, suggesting that the compound can be administered on a once-weekly schedule.

[0054] Figure 4A and Figure 4B Treatment schedule and treatment groups for huCD16TgScid mice as described in Example 5 are shown.

[0055] Figure 5A Tumor growth kinetics as observed in mice treated with trastuzumab alone, hybrid FAP-mu4-1BBL alone, or a combination of both are shown (mean + / - SEM). Individual tumor growth kinetics for each animal in all treatment groups were Figure 5B (control group), Figure 5C (treated with trastuzumab alone), Figure 5D (treated with FAP-mu4-1BBL alone) and Figure 5E The number of tumor-free mice at the end of the study is indicated. DETAILED DESCRIPTION

[0056] definition

[0057] Unless otherwise defined, technical and scientific terms used herein have the same meaning as commonly used in the art to which this invention belongs. For the purpose of interpreting this specification, the following definitions will apply, and where appropriate, terms used in the singular will also include the plural, and vice versa.

[0058] As used herein, the term "antigen binding molecule" refers in its broadest sense to a molecule that specifically binds to an antigenic determinant. Examples of antigen binding molecules are antibodies, antibody fragments and scaffold antigen binding proteins.

[0059] The term "antibody" is used herein in the broadest sense and encompasses various antibody structures, including but not limited to monoclonal antibodies, polyclonal antibodies, monospecific and multispecific antibodies (eg, bispecific antibodies), and antibody fragments, so long as they exhibit the desired antigen-binding activity.

[0060] The term "monoclonal antibody" as used herein refers to an antibody obtained from a substantial homogeneous antibody population, i.e., the individual antibodies constituting the population are identical and / or bind to the same epitope, except for possible antibody variants, e.g., containing naturally occurring mutations or produced during the generation of monoclonal antibody preparations, such variants generally being present in minute amounts. In contrast to polyclonal antibody preparations that typically include different antibodies directed against different determinants (epitopes), each monoclonal antibody in a monoclonal antibody preparation is directed against a single determinant on the antigen.

[0061] The term "monospecific" antibody as used herein refers to an antibody having one or more binding sites, each of which binds to the same epitope of the same antigen. The term "bispecific" means that an antigen binding molecule is capable of specifically binding to at least two distinct antigenic determinants. Typically, a bispecific antigen binding molecule comprises two antigen binding sites, each of which is specific to different antigenic determinants. In certain embodiments, a bispecific antigen binding molecule is capable of simultaneously binding to two antigenic determinants, particularly two antigenic determinants expressed on two distinct cells.

[0062] The term "valency" as used in this application refers to the presence of a specified number of binding sites in an antigen binding molecule. As such, the terms "divalent", "tetravalent", and "hexavalent" refer to the presence of two binding sites, four binding sites, and six binding sites in an antigen binding molecule, respectively.

[0063] The terms "full-length antibody", "intact antibody", and "whole antibody" are used interchangeably herein and refer to antibodies having a structure substantially similar to that of a natural antibody. "Native antibody" refers to naturally occurring immunoglobulin molecules having different structures. For example, natural IgG class antibodies are heterotetrameric glycoproteins of about 150,000 daltons, consisting of two light chains and two heavy chains that are disulfide bonded. From the N-terminus to the C-terminus, each heavy chain has a variable region (VH), also referred to as a variable heavy domain or a heavy chain variable domain, followed by three constant domains (CH1, CH2, and CH3), also referred to as a heavy chain constant region. Similarly, from the N-terminus to the C-terminus, each light chain has a variable region (VL), also referred to as a variable light domain or a light chain variable domain, followed by a light chain constant domain (CL), also referred to as a light chain constant region. The heavy chains of antibodies can be assigned to one of five types, called α (IgA), δ (IgD), ε (IgE), γ (IgG), or μ (IgM), some of which can be further divided into subtypes, such as γ1 (IgG1), γ2 (IgG2), γ3 (IgG3), γ4 (IgG4), α1 (IgA1) and α2 (IgA2). The light chains of antibodies can be assigned to one of two types, called kappa (κ) and lambda (λ), based on the amino acid sequence of their constant domains.

[0064] "Antibody fragment" refers to a molecule other than an intact antibody, which comprises a portion of an intact antibody that binds to the antigen to which the intact antibody binds. Examples of antibody fragments include, but are not limited to, Fv, Fab, Fab', Fab'-SH, F(ab')2; diabodies, triabodies, tetrabodies, crossover Fab fragments; linear antibodies; single-chain antibody molecules (e.g., scFv); and single-domain antibodies. For a review of certain antibody fragments, see Hudson et al., Nat Med 9, 129-134 (2003). For a review of scFv fragments, see, e.g., Plückthun, in The Pharmacology of Monoclonal Antibodies, vol. 113, Rosenburg and Moore eds., Springer-Verlag, New York, pp. 269-315 (1994); see also WO 93 / 16185; and U.S. Pat. Nos. 5,571,894 and 5,587,458. For a discussion of Fab and F(ab')2 fragments containing salvage receptor binding epitope residues and having extended in vivo half-life, see U.S. Pat. No. 5,869,046. Diabodies are antibody fragments having two antigen binding sites that can be bivalent or bispecific, see, e.g., EP 404,097; WO 1993 / 01161; Hudson et al., Nat Med 9, 129-134 (2003); and Hollinger et al., Proc Natl Acad Sci USA 90, 6444-6448 (1993). Triabodies and tetrabodies are also described in Hudson et al., Nat Med 9, 129-134 (2003). Single domain antibodies are antibody fragments that contain all or a portion of the heavy chain variable domain or all or a portion of the light chain variable domain of an antibody. In certain embodiments, the single-domain antibody is a human single-domain antibody (Domantis, Inc., Waltham, MA; see, e.g., U.S. Patent No. 6,248,516B1). Antibody fragments can be generated by various techniques, including but not limited to proteolytic digestion of intact antibodies and production by recombinant host cells (e.g., E. coli or phage), as described herein.

[0065] Papain digestion of intact antibodies generates two identical antigen-binding fragments, called "Fab" fragments, each containing heavy and light chain variable domains, as well as the constant domain of the light chain and the first constant domain (CH1) of the heavy chain. Thus, as used herein, the term "Fab fragment" refers to an antibody fragment comprising a light chain fragment comprising the VL domain and constant domain (CL) of the light chain, and the VH domain and the first constant domain (CH1) of the heavy chain. Fab' fragments differ from Fab fragments by adding a few residues at the carboxyl terminus of the heavy chain CH1 domain, including one or more cysteines from the hinge region of the antibody. Fab'-SH is a Fab' fragment in which the cysteine ​​residues of the constant domain carry free thiol groups. Pepsin treatment produces a F(ab')2 fragment having two antigen-binding sites (two Fab fragments) and a portion of the Fc region.

[0066] The term "crossover Fab fragment" or "xFab fragment" or "exchange Fab fragment" refers to a Fab fragment in which either the variable region or the constant region of the heavy and light chains is exchanged. Two different chain compositions of the exchange Fab molecule are possible and are included in the bispecific antibodies of the present invention: on the one hand, the variable regions of the Fab heavy and light chains are exchanged, i.e., the exchange Fab molecule comprises a peptide chain consisting of a light chain variable region (VL) and a heavy chain constant region (CH1), and a peptide chain consisting of a heavy chain variable region (VH) and a light chain constant region (CL). This exchange Fab molecule is also called CrossFab. (VLVH) On the other hand, when the constant regions of the heavy and light chains of Fab are exchanged, the exchange Fab molecule contains a peptide chain consisting of the heavy chain variable region (VH) and the light chain constant region (CL), and a peptide chain consisting of the light chain variable region (VL) and the heavy chain constant region (CH1). This exchange Fab molecule is also called CrossFab. (CLCH1) .

[0067] "Single-chain Fab fragments" or "scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CH1-linker-VL-CL, b) VL-CL-linker-VH-CH1, c) VH-CL-linker-VL-CH1 or d) VL-CH1-linker-VH-CL; and wherein the linker is a polypeptide of at least 30 amino acids, preferably 32 to 50 amino acids. The single-chain Fab fragments are stabilized via the native disulfide bonds between the CL domain and the CH1 domain. In addition, these single-chain Fab molecules can be further stabilized by generating interchain disulfide bonds via the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0068] "Exchange single-chain Fab fragments" or "x-scFab" are polypeptides consisting of an antibody heavy chain variable domain (VH), an antibody constant domain 1 (CH1), an antibody light chain variable domain (VL), an antibody light chain constant domain (CL) and a linker, wherein the antibody domains and the linker have one of the following orders in the N-terminal to C-terminal direction: a) VH-CL-linker-VL-CH1 and b) VL-CH1-linker-VH-CL; wherein VH and VL together form an antigen binding site that specifically binds an antigen, and wherein the linker is a polypeptide of at least 30 amino acids. In addition, these x-scFab molecules can be further stabilized by generating interchain disulfide bonds through the insertion of cysteine ​​residues (e.g., position 44 in the variable heavy chain and position 100 in the variable light chain according to Kabat numbering).

[0069] A "single-chain variable fragment (scFv)" is a heavy chain variable fragment of an antibody joined to a short linker peptide of 10 to about 25 amino acids. H ) and light (V L ) chain variable region fusion protein. The linker is often rich in glycine for flexibility, and serine or threonine for solubility, and V H The N-terminal and V L The antibody fragment is connected to the C-terminus of the antibody or vice versa. Despite the removal of the constant region and the introduction of the linker, the protein retains the specificity of the original antibody. ScFv antibodies are described in, for example, Houston, JS, Methods in Enzymol. 203 (1991) 46-96. In addition, the antibody fragment comprises a single-chain polypeptide having the characteristics of the VH domain (i.e., capable of being assembled with the VL domain) or the characteristics of the VL domain (i.e., capable of being assembled with the VH domain), and the VH domain is assembled with the VL domain into a functional antigen binding site and thereby provides the antigen binding properties of the full-length antibody.

[0070] "Scaffold antigen binding proteins" are known in the art, for example, fibronectin and designed ankyrin repeat proteins (DARPins) have been used as alternative scaffolds for antigen binding domains, see, for example, Gebauer and Skerra, Engineered protein scaffolds as next-generation antibody therapeutics. Curr Opin Chem Biol 13:245-255 (2009) and Stumpp et al., Darpins: A new generation of protein therapeutics. Drug Discovery Today 13:695-701 (2008). In one aspect of the invention, the scaffold antigen binding protein is selected from CTLA-4 (Evibody), lipocalin (Anticalin), protein A derived molecules such as the Z domain of protein A (Affibody), the A domain (Avimer / Maxibody), serum transferrin (trans-body); designed ankyrin repeat proteins (DARPin), the variable domain of the light or heavy chain of an antibody (single domain antibody, sdAb), the variable domain of the heavy chain of an antibody (nanobody, aVH), V NAR fragment, fibronectin (AdNectin), C-type lectin domain (Tetranectin); variable domain of novel antigen receptor β-lactamase (V NAR fragments), human γ-crystallin or ubiquitin (Affilin molecules); Kunitz-type domains of human protease inhibitors, microbodies, such as proteins from the knottin family, peptide aptamers and a group consisting of fibronectin (adnectin).

[0071] Lipocalins are a family of extracellular proteins that transport small hydrophobic molecules such as steroids, bilirubin, retinoids and lipids. They have a rigid β-sheet secondary structure with loops at the open end of the cone structure that can be engineered to bind different target antigens. Anticalins are between 160-180 amino acids in size and are derived from lipocalins. For further details, see Biochim Biophys Acta 1482:337-350 (2000), US7250297B1 and US20070224633.

[0072] Designed ankyrin repeat proteins (DARPins) are derived from ankyrin, a family of proteins that mediate the attachment of integral membrane proteins to the cytoskeleton. A single ankyrin repeat is a 33-residue motif consisting of two α-helices and a β-turn. By randomizing the residues in the first α-helix and β-turn of each repeat, they can be engineered to bind different target antigens. Their binding interface can be increased by increasing the number of modules (a method of affinity maturation). For further details, see J. Mol. Biol. 332, 489-503 (2003), PNAS 100 (4), 1700-1705 (2003) and J. Mol. Biol. 369, 1015-1028 (2007) and US20040132028A1.

[0073] Single domain antibodies are antibody fragments consisting of a single monomeric variable antibody domain. The first single domains are derived from the variable domains of antibody heavy chains from camelids (nanobodies or V H H fragment). Furthermore, the term single domain antibody includes autonomous human heavy chain variable domains (aVH) or VH derived from sharks. NAR Fragment.

[0074] An "antigen-binding molecule that binds to the same epitope as a reference molecule" refers to an antigen-binding molecule that blocks the binding of the reference molecule to its antigen by 50% or more in a competition assay, whereas the reference molecule blocks the binding of the antigen-binding molecule to its antigen by 50% or more in a competition assay.

[0075] The term "antigen binding domain" refers to a portion of an antigen binding molecule that contains a region that specifically binds to part or all of an antigen and is complementary. In the case where the antigen is larger, the antigen binding molecule may only bind to a specific portion of the antigen, which is called an epitope. The antigen binding domain can be provided by, for example, one or more variable domains (also referred to as variable regions). Preferably, the antigen binding domain comprises an antibody light chain variable region (VL) and an antibody heavy chain variable region (VH).

[0076] As used herein, the term "antigenic determinant" is synonymous with "antigen" and "epitope", and refers to the following site on the polypeptide macromolecule (e.g., a continuous segment of amino acids or a conformational structure consisting of different regions of discontinuous amino acids), to which the antigen binding moiety binds to form an antigen binding moiety-antigen complex. Useful antigenic determinants can be found, for example, on the surface of tumor cells, on the surface of virally infected cells, on the surface of other diseased cells, on the surface of immune cells, free in serum, and / or in the extracellular matrix (ECM). Proteins useful as antigens herein can be any native form of protein from any vertebrate source, including mammals, such as primates (e.g., humans) and rodents (e.g., mice and rats), unless otherwise specified. In a specific embodiment, the antigen is a human protein. In the case of referring to a specific protein herein, the term encompasses "full-length" unprocessed protein and any form of protein derived from processing in a cell. The term also encompasses naturally occurring variants of protein, such as splice variants or allelic variants.

[0077] "Specific binding" means that the binding is selective for the antigen and can be distinguished from unwanted or non-specific interactions. The ability of an antigen-binding molecule to bind a specific antigen can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance (SPR) technology (analyzed on a BIAcore instrument) (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). In one embodiment, the degree of binding of an antigen-binding molecule to an unrelated protein is less than about 10% of the binding of the antigen-binding molecule to the antigen, as measured by, for example, SPR. In certain embodiments, the antigen-binding molecule has a specific binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or smaller, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 The dissociation constant (Kd) of the

[0078] "Affinity" or "binding affinity" refers to the strength of the sum of non-covalent interactions between a single binding site of a molecule (e.g., an antibody) and its binding partner (e.g., an antigen). Unless otherwise indicated, as used herein, "binding affinity" refers to the intrinsic binding affinity that reflects a 1:1 interaction between members of a binding pair (e.g., an antibody and an antigen). The affinity of a molecule X for its partner Y can generally be represented by a dissociation constant (Kd), which is the dissociation and association rate constants (k, respectively). off and k on ). Thus, equivalent affinities may comprise different rate constants as long as the ratio of the rate constants remains the same. Affinity can be measured by common methods known in the art, including those described herein. One particular method for measuring affinity is surface plasmon resonance (SPR).

[0079] The term "tumor-associated antigen" means any antigen that is highly expressed by tumor cells or in the tumor stroma. Specific tumor-associated antigens are CEA or FAP.

[0080] The term "fibroblast activation protein (FAP)", also known as prolyl endopeptidase FAP or seprase (EC 3.4.21), refers to any native FAP from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise specified. The term includes "full-length" unprocessed FAP and any form of FAP derived from processing in cells. The term also encompasses naturally occurring variants of FAP, such as splice variants or allelic variants. In one embodiment, the antigen binding molecules of the present invention are capable of specifically binding to human, mouse and / or cynomolgus monkey FAP. The amino acid sequence of human FAP is shown in UniProt (www.uniprot.org) Accession No. Q12884 (version 149, SEQ ID NO: 56), or NCBI (www.ncbi.nlm.nih.gov / ) RefSeq NP_004451.2. The extracellular domain (ECD) of human FAP extends from amino acid position 26 to 760. The amino acid sequence of human FAP ECD with a His tag is shown in SEQ ID NO: 81. The amino acid sequence of mouse FAP is shown in UniProt accession number P97321 (version 126, SEQ ID NO: 58), or NCBI RefSeq NP_032012.1. The extracellular domain (ECD) of mouse FAP extends from amino acid position 26 to 761. SEQ ID NO: 83 shows the amino acid sequence of mouse FAP ECD with a His tag. SEQ ID NO: 84 shows the amino acid sequence of cynomolgus monkey FAP ECD with a His tag. Preferably, the anti-FAP binding molecules of the present invention bind to the extracellular domain of FAP. Exemplary anti-FAP binding molecules are described in International Patent Application No. WO 2012 / 020006 A2.

[0081] The term "carcinoembryonic antigen (CEA)", also known as carcinoembryonic antigen-related cell adhesion molecule 5 (CEACAM5), refers to any native CEA from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The amino acid sequence of human CEA is shown in UniProt accession number P06731 (version 151, SEQ ID NO: 61). CEA has long been identified as a tumor-associated antigen (Gold and Freedman, J Exp Med., 121: 439-462, 1965; Berinstein NL, J Clin Oncol., 20: 2197-2207, 2002). Initially classified as a protein expressed only in fetal tissues, CEA has now been identified in several normal adult tissues. These tissues are primarily of epithelial origin, including cells of the gastrointestinal, respiratory, and urogenital tracts, and cells of the colon, cervix, sweat glands, and prostate (Nap et al., Tumour Biol., 9(2-3):145-53, 1988; Nap et al., Cancer Res., 52(8):2329-23339, 1992). Tumors of epithelial origin and their metastases contain CEA as a tumor-associated antigen. Although the presence of CEA itself does not indicate transformation into cancerous cells, the distribution of CEA is indicative. In normal tissues, CEA is generally expressed on the apical surface of cells ( Semin Cancer Biol. 9(2):67-81(1999)), making it inaccessible to antibodies in the bloodstream. In contrast to normal tissues, CEA tends to be expressed on the entire surface of cancerous cells ( Semin Cancer Biol. 9(2):67-81(1999)). This change in expression pattern makes CEA accessible for antibody binding in cancerous cells. In addition, CEA expression is elevated in cancerous cells. Moreover, elevated CEA expression promotes increased cell-cell adhesion, which can lead to metastasis (Marshall J., Semin Oncol., 30(a Suppl. 8):30-6, 2003). The prevalence of CEA expression in various tumor entities is generally high. Consistent with published data, own analysis in tissue samples confirmed its high prevalence, approximately 95% in colorectal cancer (CRC), 90% in pancreatic cancer, 80% in gastric cancer, 60% in non-small cell lung cancer (NSCLC, in which case it is co-expressed with HER3), and 40% in breast cancer; low expression was found in small cell lung cancer and glioblastoma.

[0082] CEA is easily cleaved from the cell surface and shed from the tumor into the bloodstream either directly or via lymphocytes. Due to this property, the level of serum CEA has been used as a clinical marker for diagnosing cancer and screening for cancer, especially recurrence of colorectal cancer (Goldenberg DM., The International Journal of Biological Markers, 7:183-188, 1992; Chau I. et al., J Clin Oncol., 22:1420-1429, 2004; Flamini et al., Clin Cancer Res., 12(23):6985-6988, 2006).

[0083] As used herein, "T cell antigen" refers to an antigenic determinant presented on the surface of T lymphocytes, particularly cytotoxic T lymphocytes.

[0084] As used herein, a "T cell activating therapeutic agent" refers to a therapeutic agent capable of inducing T cell activation in a subject, particularly a therapeutic agent designed to induce T cell activation in a subject.

[0085] As used herein, "activating T cell antigen" refers to an antigenic determinant expressed by T lymphocytes, particularly cytotoxic T lymphocytes, which can induce or enhance T cell activation after interacting with an antigen binding molecule. In particular, the interaction of an antigen binding molecule with an activating T cell antigen can induce T cell activation, which is carried out by triggering the signal transduction cascade of the T cell receptor complex. An exemplary activating T cell antigen is CD3.

[0086] The term "variable region" or "variable domain" refers to the domain of an antibody heavy or light chain that is involved in the binding of an antigen-binding molecule to an antigen. The variable domains of the heavy and light chains of natural antibodies (VH and VL, respectively) generally have similar structures, with each domain comprising four conserved framework regions (FRs) and three hypervariable regions (HVRs). See, e.g., Kindt et al., Kuby Immunology, 6th ed., WH Freeman and Co., p. 91 (2007). A single VH or VL domain may be sufficient to confer antigen binding specificity.

[0087] As used herein, the term "hypervariable region" or "HVR" refers to each region of an antibody variable domain that is highly variable in sequence and / or forms a structurally defined loop ("hypervariable loop"). Typically, a natural four-chain antibody comprises six HVRs: three in VH (H1, H2, H3) and three in VL (L1, L2, L3). HVRs generally comprise amino acid residues from hypervariable loops and / or from "complementarity determining regions" (CDRs), which have the highest sequence variability and / or are involved in antigen recognition. Exemplary hypervariable loops occur at amino acid residues 26-32 (L1), 50-52 (L2), 91-96 (L3), 26-32 (H1), 53-55 (H2), and 96-101 (H3) (Chothia and Lesk, J. Mol. Biol. 196: 901-917 (1987)). Exemplary CDRs (CDR-L1, CDR-L2, CDR-L3, CDR-H1, CDR-H2, and CDR-H3) occur at amino acid residues 24-34 (L1), 50-56 (L2), 89-97 (L3), 31-35B (H1), 50-65 (H2), and 95-102 (H3) (Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD (1991)). Hypervariable regions (HVRs) are also called complementarity determining regions (CDRs), and these terms are used interchangeably herein when referring to the portions of the variable domains that form the antigen binding region. This particular region has been described by Kabat et al., U. S. Pat. of Health and Human Services, "Sequences of Proteins of Immunological Interest" (1983) and by Chothia et al., J. Mol. Biol. 196: 901-917 (1987), wherein the definitions include overlaps or subsets of amino acid residues when compared to each other. In any case, the application of any definition to refer to the CDR of an antibody or its variants is intended to be within the scope of the term as defined and used herein. Suitable amino acid residues covering the CDRs defined by each of the references cited above are listed as a comparison in Table A below. The exact residue number covering a particular CDR will vary depending on the sequence and size of the CDR. Based on the variable region amino acid sequence of an antibody, those skilled in the art can routinely determine which residues constitute a particular CDR.

[0088] Table A: CDR Definition 1

[0089] CDR Kabat Chothia <![CDATA[AbM 2 ]]> <![CDATA[V H CDR1]]> 31-35 26-32 26-35 <![CDATA[V H CDR2]]> 50-65 52-58 50-58 <![CDATA[V H CDR3]]> 95-102 95-102 95-102 <![CDATA[V L CDR1]]> 24-34 26-32 24-34 <![CDATA[V L CDR2]]> 50-56 50-52 50-56 <![CDATA[V L CDR3]]> 89-97 91-96 89-97

[0090] 1 The numbering of all CDR definitions in Table A follows the numbering convention outlined by Kabat et al. (see below). 2 "AbM" with a lowercase "b" as used in Table A refers to CDRs as defined by Oxford Molecular's "AbM" antibody modeling software.

[0091] Kabat et al. also defined a numbering system applicable to the variable region sequences of any antibody. One of ordinary skill in the art can clearly assign this system of "Kabat numbering" to any variable region sequence, independent of any experimental data beyond the sequence itself. As used herein, "Kabat numbering" refers to the numbering system listed in Kabat et al., US Pat. of Health and Human Services, "Sequence of Proteins of Immunological Interest" (1983). Unless otherwise specified, reference to the numbering of specific amino acid residue positions in antibody variable regions is in accordance with the Kabat numbering system.

[0092] In addition to the CDR1 in VH, CDRs generally include amino acid residues that form hypervariable loops. CDRs also include "specificity determining residues" or "SDRs," which are residues that contact antigens. SDRs are included in CDR regions called shortened CDRs or a-CDRs. Exemplary a-CDRs (a-CDR-L1, a-CDR-L2, a-CDR-L3, a-CDR-H1, a-CDR-H2, and a-CDR-H3) occur at amino acid residues 31-34 (L1), 50-55 (L2), 89-96 (L3), 31-35B (H1), 50-58 (H2), and 95-102 (H3) (see Almagro and Fransson, Front. Biosci. 13: 1619-1633 (2008)). Unless otherwise indicated, HVR residues and other residues in the variable domain (eg, FR residues) are numbered herein according to Kabat et al., supra.

[0093] As used herein, the term "affinity matured" in the context of an antigen binding molecule (e.g., an antibody) refers to an antigen binding molecule that is derived, for example by mutation, from a reference antigen binding molecule, binds to the same antigen, preferably to the same epitope, as the reference antibody; and has a higher affinity for the antigen than the reference antigen binding molecule. Affinity maturation generally involves modifying one or more amino acid residues in one or more CDRs of the antigen binding molecule. Typically, the affinity matured antigen binding molecule binds to the same epitope as the initial reference antigen binding molecule.

[0094] "Framework" or "FR" refers to variable domain residues other than hypervariable region (HVR) residues. The FR of a variable domain generally consists of four FR domains: FR1, FR2, FR3, and FR4. Thus, HVR and FR sequences generally appear in the following order in VH (or VL): FR1-H1 (L1)-FR2-H2 (L2)-FR3-H3 (L3)-FR4.

[0095] For purposes herein, an "acceptor human framework" is a framework comprising an amino acid sequence of a light chain variable domain (VL) framework or a heavy chain variable domain (VH) framework derived from a human immunoglobulin framework or a human consensus framework as defined below. An acceptor human framework "derived" from a human immunoglobulin framework or a human consensus framework may comprise the same amino acid sequence thereof, or it may contain amino acid sequence changes. In some embodiments, the number of amino acid changes is 10 or less, 9 or less, 8 or less, 7 or less, 6 or less, 5 or less, 4 or less, 3 or less, or 2 or less. In some embodiments, the VL acceptor human framework is identical in sequence to a VL human immunoglobulin framework sequence or a human consensus framework sequence.

[0096] The term "chimeric" antibody refers to an antibody in which a portion of the heavy and / or light chain is derived from a particular source or species, while the remainder of the heavy and / or light chain is derived from a different source or species.

[0097] The "class" of an antibody refers to the type of constant domain or constant region possessed by its heavy chain. There are five major classes of antibodies: IgA, IgD, IgE, IgG, and IgM, and several of them can be further divided into subclasses (isotypes), such as IgG1, IgG2, IgG3, IgG4, IgA1, and IgA2. The heavy chain constant domains corresponding to the different classes of immunoglobulins are called α, δ, ε, γ, and μ, respectively.

[0098] A "humanized" antibody refers to a chimeric antibody comprising amino acid residues from non-human HVRs and amino acid residues from human FRs. In certain embodiments, a humanized antibody will comprise at least one, typically two substantially entire variable domains, wherein the entire or substantially entire HVRs (e.g., CDRs) correspond to those of a non-human antibody, and the entire or substantially entire FRs correspond to those of a human antibody. A humanized antibody may optionally comprise at least a portion of an antibody constant region derived from a human antibody. A "humanized form" of an antibody, such as a non-human antibody, refers to an antibody that has undergone humanization. Other forms of "humanized antibodies" encompassed by the present invention are those in which the constant region has been additionally modified or altered from that of the original antibody to generate properties in accordance with the present invention, particularly those with respect to C1q binding and / or Fc receptor (FcR) binding.

[0099] A "human" antibody is an antibody that possesses an amino acid sequence that corresponds to the amino acid sequence of an antibody produced by a human or human cell or derived from a non-human source utilizing a human antibody repertoire or other human antibody encoding sequences. This definition of a human antibody specifically excludes humanized antibodies comprising non-human antigen-binding residues.

[0100] The term "Fc domain" or "Fc region" herein is used to define the C-terminal region of an antibody heavy chain containing at least a portion of a constant region. The term includes native sequence Fc regions and variant Fc regions. The IgG Fc region comprises IgG CH2 and IgG CH3 domains. The "CH2 domain" of the human IgG Fc region generally extends from an amino acid residue at about position 231 to an amino acid residue at about position 340. In one embodiment, a carbohydrate chain is attached to the CH2 domain. The CH2 domain herein may be a native sequence CH2 domain or a variant CH2 domain. The "CH3 domain" comprises the residues at the C-terminus of the CH2 domain in the Fc region (i.e., from an amino acid residue at about position 341 of IgG to an amino acid residue at about position 447). The CH3 region herein may be a native sequence CH3 domain or a variant CH3 domain (e.g., a CH3 domain having a "protuberance" ("section") introduced in one of its chains and a "cavity" ("hole") introduced correspondingly in the other chain; see U.S. Patent No. 5,821,333, expressly incorporated herein by reference). As described herein, such variant CH3 domains can be used to promote heterodimerization of two different antibody heavy chains. In one embodiment, the human IgG heavy chain Fc region extends from Cys226 or from Pro230 to the carboxyl terminus of the heavy chain. However, the C-terminal lysine (Lys447) in the Fc region may be present or absent. Unless otherwise specified herein, the numbering of amino acid residues in the Fc region or constant region is according to the EU numbering system, also referred to as the EU index, as described in Kabat et al., Sequences of Proteins of Immunological Interest, 5th Ed. Public Health Service, National Institutes of Health, Bethesda, MD, 1991.

[0101] The "knob-into-hole" technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide, such that the protuberance can be placed in the cavity, thereby promoting heterodimer formation and hindering homodimer formation. The protuberance is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity of the same or similar size as the protuberance is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller side chain (e.g., alanine or threonine). The protuberance and cavity can be generated by altering the nucleic acid encoding the polypeptide, for example, by site-specific mutagenesis, or by peptide synthesis. In a specific embodiment, the knob modification comprises the amino acid substitution T366W in one of the two subunits of the Fc domain, and the hole modification comprises the amino acid substitutions T366S, L368A and Y407V in the other of the two subunits of the Fc domain. In yet another specific embodiment, the subunit comprising the knob modification in the Fc domain further comprises the amino acid substitution S354C, and the subunit comprising the hole modification in the Fc domain further comprises the amino acid substitution Y349C. The introduction of these two cysteine ​​residues results in the formation of a disulfide bridge between the two subunits of the Fc region, thus further stabilizing the dimer (Carter, J Immunol Methods 248, 7-15 (2001)).

[0102] "Regions equivalent to the Fc region of an immunoglobulin" are intended to include naturally occurring allelic variants of the Fc region of an immunoglobulin and variants that have produced alterations of substitution, addition, or deletion but do not substantially reduce the ability of the immunoglobulin to mediate effector functions (such as antibody-dependent cellular cytotoxicity). For example, one or more amino acids may be deleted from the N-terminus or C-terminus of the Fc region of an immunoglobulin without substantial loss of biological function. Such variants may be selected according to general rules known in the art so as to have minimal effect on activity (see, e.g., Bowie, JU et al., Science 247: 1306-10 (1990)).

[0103] The term "effector function" refers to those biological activities attributable to the Fc region of an antibody, which vary with the antibody isotype. Examples of antibody effector functions include: C1q binding and complement dependent cytotoxicity (CDC), Fc receptor binding, antibody-dependent cell-mediated cytotoxicity (ADCC), antibody-dependent cellular phagocytosis (ADCP), cytokine secretion, immune complex-mediated antigen-presenting cell uptake of antigens, downregulation of cell surface receptors (e.g., B cell receptors), and B cell activation.

[0104] An "activating Fc receptor" is an Fc receptor that, upon engagement by the Fc region of an antibody, initiates a signaling event that stimulates cells bearing the receptor to perform effector functions. Activating Fc receptors include FcγRIIIa (CD16a), FcγRI (CD64), FcγRIIa (CD32), and FcαRI (CD89). One specific activating Fc receptor is human FcγRIIIa (see UniProt Accession No. P08637, version 141).

[0105] "Extraterrestrial domain" is a domain extending into the extracellular space (i.e., space outside the target cell) in a membrane protein.Extraterrestrial domains are usually the part that starts contact with the surface in a protein, which leads to signal transduction.Thus, the extraterrestrial domain of 4-1BBL as defined herein refers to the part (extracellular domain) extending into the extracellular space in 4-1BBL, but also includes a shorter part or its fragment responsible for trimerization and binding to the corresponding receptor 4-1BB.Thus, the term "extraterrestrial domain or its fragment" refers to the extracellular domain forming the extracellular domain in 4-1BBL or the part (receptor binding domain) that it is still able to bind to a receptor.

[0106] "4-1BBL" or "4-1BB ligand" or "CD137L" is a costimulatory TNF ligand family member that can costimulate the proliferation of T cells and cytokine production. Costimulatory TNF family ligands can costimulate TCR signals when interacting with their corresponding TNF receptors, and the interaction with their receptors leads to the recruitment of TNFR-associated factors (TRAFs), which initiates the signal transduction cascade leading to T cell activation. 4-1BBL is a type II transmembrane protein. It has been described that the complete or full-length 4-1BBL with the amino acid sequence of SEQ ID NO:62 forms a trimer on the surface of the cell. The formation of trimers is achieved by the specific motifs of the outer domains of 4-1BBL. The motif is named "trimerization region" in this article. The amino acids 50-254 (SEQ ID NO:63) of the human 4-1BBL sequence form the extracellular domain of 4-1BBL, but even its fragments can form trimers. In a specific embodiment of the present invention, the term "exodomain of 4-1BBL or a fragment thereof" refers to a polypeptide having an amino acid sequence selected from SEQ ID NO: 4 (amino acids 52-254 of human 4-1BBL), SEQ ID NO: 1 (amino acids 71-254 of human 4-1BBL), SEQ ID NO: 3 (amino acids 80-254 of human 4-1BBL), SEQ ID NO: 2 (amino acids 85-254 of human 4-1BBL), SEQ ID NO: 5 (amino acids 71-248 of human 4-1BBL), SEQ ID NO: 6 (amino acids 85-248 of human 4-1BBL), SEQ ID NO: 7 (amino acids 80-248 of human 4-1BBL) and SEQ ID NO: 8 (amino acids 52-248 of human 4-1BBL), but other fragments of the extradomain capable of trimerization are also included herein.

[0107] As used herein, the term "4-1BB" or "CD137" refers to any natural 4-1BB from any vertebrate source, including mammals, such as primates (eg, humans) and rodents (eg, mice and rats), unless otherwise specified. The term encompasses "full length", unprocessed 4-1BB and any form of 4-1BB processed from cells. The term also encompasses naturally occurring variants of 4-1BB, such as splice variants or allelic variants. An exemplary human 4-1BB amino acid sequence is shown in SEQ ID NO: 88 (Uniprot accession number Q07011), an exemplary mouse 4-1BB amino acid sequence is shown in SEQ ID NO: 89 (Uniprot accession number P20334) and an exemplary cynomolgus monkey 4-1BB (from macaque (Macaca mulatta)) amino acid sequence is shown in SEQ ID NO: 66 (Uniprot accession number F6W5G6).

[0108] The terms "anti-4-1BB antibody", "anti-4-1BB", "4-1BB antibody" and "antibody that specifically binds to 4-1BB" refer to an antibody that is capable of binding to 4-1BB with sufficient affinity so that the antibody can be used as a diagnostic and / or therapeutic agent in targeting 4-1BB. In one embodiment, the extent of binding of the anti-4-1BB antibody to an unrelated, non-4-1BB protein is less than about 10% of the binding of the antibody to 4-1BB, as measured, for example, by radioimmunoassay (RIA) or flow cytometry (FACS). In certain embodiments, the antibody that binds to 4-1BB has a binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -6 M or less, e.g. 10 -68 M to 10 -13 M, for example 10 -8 M to 10 -10 The dissociation constant (K D ).

[0109] The term "HER-2" (also referred to as "ErbB2", "ErbB2 receptor", or "c-Erb-B2") refers to any native, mature HER-2 derived from the processing of a HER-2 precursor protein in a cell. The term includes HER-2 from any vertebrate source, including mammals, such as primates (e.g., humans and cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The term also includes naturally occurring variants of HER-2, such as splice variants or allelic variants. The amino acid sequence of an exemplary human HER-2 protein is shown in SEQ ID NO: 95.

[0110] The term "peptide linker" refers to a peptide comprising one or more amino acids, typically about 2-20 amino acids. Peptide linkers are known in the art or described herein. Suitable non-immunogenic linker peptides are, for example, (G4S) n , (SG4) n or G4(SG4) n A peptide linker wherein "n" is generally a number between 1 and 10, typically between 2 and 4, in particular 2, i.e. the peptide is selected from the group consisting of GGGGS (SEQ ID NO:67) GGGGSGGGGS (SEQ ID NO:68), SGGGGSGGGG (SEQ ID NO:69) and GGGGSGGGGSGGGG (SEQ ID NO:70), but also includes the sequence GSPGSSSSGS (SEQ ID NO:71), (G4S)3 (SEQ ID NO:72), (G4S)4 (SEQ ID NO:73), GSGSGSGS (SEQ ID NO:74), GSGSGNGS (SEQ ID NO:75), GGSGSGSG (SEQ ID NO:76), GGSGSG (SEQ ID NO:77), GGSG (SEQ ID NO:78), GGSGNGSG (SEQ ID NO:79), GGNGSGSG (SEQ ID NO:80). Peptide linkers of particular interest are (G4S) (SEQ ID NO: 67), (G4S)2 and GGGGSGGGGS (SEQ ID NO: 68).

[0111] As used within this application, the term "amino acid" refers to the group of naturally occurring carboxyl α-amino acids, including alanine (three letter code: ala, single letter code: A), arginine (arg, R), asparagine (asn, N), aspartic acid (asp, D), cysteine ​​(cys, C), glutamine (gln, Q), glutamic acid (glu, E), glycine (gly, G), histidine (his, H), isoleucine (ile, I), leucine (leu, L), lysine (lys, K), methionine (met, M), phenylalanine (phe, F), proline (pro, P), serine (ser, S), threonine (thr, T), tryptophan (trp, W), tyrosine (tyr, Y), and valine (val, V).

[0112] "Fused" or "linked" means that the components (eg, the polypeptide and the external domain of 4-1BBL) are linked by peptide bonds, either directly or via one or more peptide linkers.

[0113] "Percent (%) amino acid sequence identity" with respect to a reference polypeptide (protein) sequence is defined as the percentage of amino acid residues in a candidate sequence that are identical to the amino acid residues in a reference polypeptide sequence after aligning the sequences and introducing gaps, if necessary, to achieve maximum percentage sequence identity, and without considering any conservative substitutions as part of sequence identity. Alignment for the purpose of determining percentage amino acid sequence identity can be achieved in a variety of ways within the skill of the art, for example using publicly available computer software such as BLAST, BLAST-2, ALIGN.SAWI or Megalign (DNASTAR) software. Those skilled in the art can determine suitable parameters for aligning sequences, including any algorithm required to achieve maximum alignment over the full length of the compared sequences. However, for purposes herein, the sequence comparison computer program ALIGN-2 is used to generate % amino acid sequence identity values. The ALIGN-2 sequence comparison computer program is written by Genentech, and the source code has been submitted to the U.S. Copyright Office (Washington DC, 20559) with user documentation, registered with U.S. Copyright Registration No. TXU510087. The public can obtain the ALIGN-2 program from Genentech (South San Francisco, California), or can compile from the source code. The ALIGN-2 program should be compiled to be used on a UNIX operating system, including digital UNIX V4.0D. All sequence comparison parameters are set by the ALIGN-2 program and remain unchanged. In the case of using ALIGN-2 to compare amino acid sequences, the % amino acid sequence identity of a given amino acid sequence A relative to (to), with (with), or for (against) a given amino acid sequence B (or it can be expressed as a given amino acid sequence A having or comprising a certain % amino acid sequence identity relative to, with, or for a given amino acid sequence B) is calculated as follows:

[0114] Multiply the fraction X / Y by 100

[0115] wherein X is the number of amino acid residues scored as identical matches by the sequence alignment program ALIGN-2 in that program's alignment of A and B, and wherein Y is the total number of amino acid residues in B. It will be appreciated that in cases where the length of amino acid sequence A is not equal to the length of amino acid sequence B, the % amino acid sequence identity of A to B will not equal the % amino acid sequence identity of B to A. Unless specifically stated otherwise, all % amino acid sequence identity values ​​used herein are obtained using the ALIGN-2 computer program as described in the immediately preceding paragraph.

[0116] In certain embodiments, amino acid sequence variants of antigen binding molecules provided herein are contemplated. For example, it may be desirable to improve the binding affinity and / or other biological properties of antigen binding molecules. The amino acid sequence variants of antigen binding molecules can be prepared by introducing suitable modifications into the nucleotide sequence encoding the molecule, or by peptide synthesis. Such modifications include, for example, deletion of residues in the amino acid sequence of an antibody, and / or insertion and / or substitution. Any combination of deletion, insertion, and substitution can be performed to obtain the final construct, provided that the final construct has desired features, such as antigen binding. The sites of interest for substitution mutagenesis include HVR and framework (FR). Conservative substitutions are provided in Table B under the heading "preferably substituted" and are further described below with reference to amino acid side chain categories (1) to (6). Amino acid substitutions can be introduced into a molecule of interest and the product screened for desired activity, such as retained / improved antigen binding, reduced immunogenicity, or improved ADCC or CDC.

[0117] Table B

[0118]

[0119]

[0120] Amino acids can be grouped according to common side chain properties:

[0121] (1) Hydrophobic: norleucine, Met, Ala, Val, Leu, Ile;

[0122] (2) Neutral hydrophilic: Cys, Ser, Thr, Asn, Gln;

[0123] (3) Acidic: Asp, Glu;

[0124] (4) Basic: His, Lys, Arg;

[0125] (5) Residues that affect chain orientation: Gly, Pro;

[0126] (6) Aromatic: Trp, Tyr, Phe.

[0127] Non-conservative substitutions will entail exchanging a member of one of these classes for a member of another class.

[0128] The term "amino acid sequence variant" includes a substantial variant in which one or more hypervariable region residues of a parent antigen binding molecule (e.g., humanized or human antibody) have amino acid substitutions. Generally, the obtained variant selected for further study will have changes (e.g., improvements) of certain biological properties relative to the parent antigen binding molecule (e.g., affinity of the increase, immunogenicity of the decrease) and / or will substantially retain certain biological properties of the parent antigen binding molecule. Exemplary substitution variants are affinity-matured antibodies, which can be conveniently generated, for example, using affinity maturation techniques based on phage display such as those described herein. In short, one or more CDR residues are mutated and the variant antigen binding molecule is displayed on phage and screened for specific biological activity (e.g., binding affinity). In certain embodiments, substitution, insertion, or deletion can occur in one or more CDRs, as long as such changes do not substantially reduce the ability of the antigen binding molecule to bind to antigens. For example, conservative changes (e.g., conservative substitutions as provided herein) that do not substantially reduce binding affinity can be performed in CDR. A method useful for identifying residues or regions that can be used as mutagenesis targets in antibodies is called "alanine scanning mutagenesis", as described by Cunningham and Wells (1989) Science, 244: 1081-1085. In this method, groups of residues or target residues (e.g., charged residues, such as Arg, Asp, His, Lys, and Glu) are identified and replaced with neutral or negatively charged amino acids (e.g., alanine or polyalanine) to determine whether the interaction of the antibody with the antigen is affected. Further substitutions can be introduced at amino acid positions that indicate functional sensitivity to the initial substitution. Alternatively or in addition, the contact points between the antibody and the antigen are identified using the crystal structure of the antigen-antigen binding molecule complex. As a candidate for substitution, such contact residues and adjacent residues can be targeted or eliminated. Variants can be screened to determine whether they contain desired properties.

[0129] The amino acid sequence insertion comprises that the length range is 1 residue to the amino and / or carboxyl terminal fusion of the polypeptide containing 100 or more residues, and the sequence intra-insertion of single or multiple amino acid residues.The example of terminal insertion comprises the antigen binding molecules with N-terminal methionyl residue.Other insertion variants of molecule comprise the fusion of N or C-terminal of the polypeptide of extending the serum half-life of antigen binding molecules.

[0130] In certain embodiments, the antigen binding molecules provided herein are changed to increase or decrease the degree of antibody glycosylation. The glycosylation variants of the molecule can be easily obtained by changing the amino acid sequence so that one or more glycosylation sites are created or removed. In the case where the antigen binding molecule includes an Fc region, the carbohydrate attached thereto can be changed. The natural antibodies generated by mammalian cells typically include branched biantennary oligosaccharides, which are generally attached to the Asn297 of the CH2 domain of the Fc region by N connection. See, for example, Wright et al., TIBTECH 15: 26-32 (1997). Oligosaccharides may include various carbohydrates, such as mannose, N-acetylglucosamine (GlcNAc), galactose, and sialic acid, as well as fucose of GlcNAc attached to the "trunk" of the biantennary oligosaccharide structure. In some embodiments, modification of the oligosaccharides in the antigen binding molecules may be performed to create variants with certain improved properties. In one aspect, variants of antigen binding molecules having a carbohydrate structure lacking fucose attached to the Fc region (directly or indirectly) are provided. Such fucosylation variants may have improved ADCC function, see, for example, U.S. Patent Publication No. US2003 / 0157108 (Presta, L.) or US2004 / 0093621 (Kyowa Hakko Kogyo Co., Ltd.). Other variants of the antigen binding molecules of the present invention include those with bisected oligosaccharides, for example, wherein the biantennary oligosaccharide attached to the Fc region is bisected by GlcNAc. Such variants may have reduced fucosylation and / or improved ADCC function, see, for example, WO 2003 / 011878 (Jean-Mairet et al.); U.S. Patent No. 6,602,684 (Umana et al.); and US 2005 / 0123546 (Umana et al.). Variants having at least one galactose residue in the oligosaccharide attached to the Fc region are also provided. Such antibody variants may have improved CDC function and are described, for example, in WO 1997 / 30087 (Patel et al.); WO 1998 / 58964 (Raju, S.); and WO 1999 / 22764 (Raju, S.).

[0131] In certain embodiments, it may be desirable to create a variant of the cysteine ​​engineering of the antigen binding molecules of the present invention, such as "thioMAb", in which one or more residues of the molecule are replaced with cysteine ​​residues. In a specific embodiment, the substituted residues appear in the accessible sites of the molecule. By replacing those residues with cysteine, the reactive thiol group is placed in the accessible sites of the antibody and can be used to conjugate the antibody with other modules such as drug modules or linker-drug modules to create an immunoconjugate. In certain embodiments, any one or more of the following residues can be replaced with cysteine: V205 (Kabat numbering) of the light chain; A118 (EU numbering) of the heavy chain; and S400 (EU numbering) in the heavy chain Fc region. Antigen binding molecules engineered with cysteine ​​can be generated as described in, for example, U.S. Patent No. 7,521,541.

[0132] In some aspects, the antigen binding molecules provided herein can be further modified to contain additional non-protein modules known in the art and readily available. Modules suitable for antibody derivatization include, but are not limited to, water-soluble polymers. Non-limiting examples of water-soluble polymers include, but are not limited to, polyethylene glycol (PEG), ethylene glycol / propylene glycol copolymers, carboxymethyl cellulose, dextran, polyvinyl alcohol, polyvinyl pyrrolidone, poly-1,3-dioxolane, poly-1,3,6-trioxane, ethylene / maleic anhydride copolymers, polyamino acids (either homopolymers or random copolymers), and dextran or poly (n-vinyl pyrrolidone) polyethylene glycol, propylene glycol homopolymers, propylene oxide / ethylene oxide copolymers, polyoxyethylated polyols (e.g., glycerol), polyvinyl alcohol, and mixtures thereof. Due to its stability in water, polyethylene glycol propionaldehyde may have advantages in manufacturing. The polymer can be of any molecular weight and can be branched or unbranched. The number of polymers attached to the antibody can vary, and if more than one polymer is attached, they can be the same or different molecules. In general, the number and / or type of polymers used for derivatization can be determined based on the following considerations, including but not limited to the specific properties or functions of the antibody to be improved, whether the bispecific antibody derivative will be used for therapy under defined conditions, etc. In another aspect, a conjugate of an antibody and a non-proteinaceous moiety that can be selectively heated by exposure to radiation is provided. In one embodiment, the non-proteinaceous moiety is a carbon nanotube (Kam, NW et al., Proc. Natl. Acad. Sci. USA 102 (2005) 11600-11605). The radiation can be of any wavelength, and includes but is not limited to wavelengths that are not harmful to ordinary cells, but heat the non-proteinaceous moiety to a temperature at which cells near the antibody-non-proteinaceous moiety are killed.

[0133] In another aspect, an immunoconjugate containing an antigen binding molecule of 4-1BBL provided herein can be obtained.An "immunoconjugate" is an antibody conjugated to one or more heterologous molecules including, but not limited to, a cytotoxic agent.

[0134] The term "polynucleotide" refers to an isolated nucleic acid molecule or construct, such as messenger RNA (mRNA), virally derived RNA, or plasmid DNA (pDNA). A polynucleotide may contain conventional phosphodiester bonds or unconventional bonds (e.g., amide bonds, such as those found in peptide nucleic acids (PNA)). The term "nucleic acid molecule" refers to any one or more nucleic acid segments, such as DNA or RNA fragments, present in a polynucleotide.

[0135] "Isolated" nucleic acid molecules or polynucleotides mean nucleic acid molecules, DNA or RNA, that have been removed from their natural environment. For example, for the purposes of the present invention, it is considered that the recombinant polynucleotides encoding polypeptides contained in the vector are isolated. Other examples of isolated polynucleotides include recombinant polynucleotides maintained in heterologous host cells or polynucleotides purified (partially or substantially) in solution. Isolated polynucleotides include polynucleotide molecules contained in cells that usually contain the polynucleotide molecules, but the polynucleotide molecules are present in extrachromosomal or chromosomal locations different from their natural chromosomal locations. Isolated RNA molecules include in vivo or in vitro RNA transcripts of the present invention, as well as positive and negative strand forms, and double-stranded forms. Polynucleotides or nucleic acids according to the separation of the present invention further include such molecules generated synthetically. In addition, polynucleotides or nucleic acids can be or can include regulatory elements, such as promoters, ribosome binding sites, or transcription terminators.

[0136] A nucleic acid or polynucleotide having a nucleotide sequence that is at least, for example, 95% "identical" to a reference nucleotide sequence of the invention means that the nucleotide sequence of the polynucleotide is identical to the reference sequence except that the polynucleotide sequence may include up to 5 point mutations per every 100 nucleotides of the reference nucleotide sequence. In other words, to obtain a polynucleotide having a nucleotide sequence that is at least 95% identical to a reference nucleotide sequence, up to 5% of the nucleotides in the reference sequence may be deleted or replaced with another nucleotide, or, in the reference sequence, a plurality of nucleotides up to 5% of the total nucleotides may be inserted into the reference sequence. These changes in the reference sequence may occur at the 5' or 3' terminal positions of the reference nucleotide sequence or anywhere between those terminal positions, either interspersed individually between residues in the reference sequence or interspersed in one or more consecutive groups within the reference sequence. In practice, whether any particular polynucleotide sequence is at least 80%, 85%, 90%, 95%, 96%, 97%, 98% or 99% identical to a nucleotide sequence of the invention can be routinely determined using known computer programs, such as those discussed above with respect to polypeptides (e.g., ALIGN-2).

[0137] The term "expression cassette" refers to a recombinant or synthetically generated polynucleotide having a series of defined nucleic acid elements that allow a specific nucleic acid to be transcribed in a target cell. The recombinant expression cassette can be incorporated into a plasmid, chromosome, mitochondrial DNA, plastid DNA, virus, or nucleic acid fragment. Typically, the recombinant expression cassette portion of the expression vector includes, in addition to other sequences, a nucleic acid sequence to be transcribed and a promoter. In certain embodiments, the expression cassette of the present invention comprises a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0138] The term "vector" or "expression vector" is synonymous with "expression construct" and refers to a DNA molecule used to introduce a specific gene operably associated therewith into a target cell and direct expression. The term includes vectors that are self-replicating nucleic acid structures as well as vectors that are incorporated into the genome of a host cell into which it has been introduced. The expression vector of the present invention comprises an expression cassette. The expression vector allows for the transcription of a large amount of stable mRNA. Once the expression vector is in the target cell, the ribonucleic acid molecule or protein encoded by the gene is generated by the cell's transcription and / or translation machinery. In one embodiment, the expression vector of the present invention comprises an expression cassette comprising a polynucleotide sequence encoding a bispecific antigen binding molecule of the present invention or a fragment thereof.

[0139] The terms "host cell", "host cell line", and "host cell culture" are used interchangeably and refer to cells into which exogenous nucleic acids have been introduced, including the offspring of such cells. Host cells include "transformants / transformants" and "transformed cells", which include primary transformed cells and offspring derived therefrom, regardless of the number of passages. Offspring may not be completely identical to parental cells in terms of nucleic acid content, but may contain mutations. Mutant offspring with the same function or biological activity as screened or selected in the original transformed cells are included herein. Host cells are any type of cell system that can be used to generate the bispecific antigen binding molecules of the present invention. Host cells include cultured cells, such as cultured mammalian cells, such as CHO cells, BHK cells, NS0 cells, SP2 / 0 cells, YO myeloma cells, P3X63 mouse myeloma cells, PER cells, PER.C6 cells or hybridoma cells, yeast cells, insect cells, and plant cells, only a few are listed, but there are also transgenic animals, transgenic plants or cells contained in cultured plants or animal tissues.

[0140] An "effective amount" of an agent is that amount necessary to cause a physiological change in the cells or tissues to which it is administered.

[0141] Combination therapy according to the present invention has a synergistic effect. A "synergistic effect" of two compounds is as follows, wherein the effect of the combination of the two agents is greater than the sum of their individual effects and is statistically different from the control and single drug. In another embodiment, the combination therapy disclosed herein has an additive effect. A "additive effect" of two compounds is as follows, wherein the effect of the combination of the two agents is the sum of their individual effects and is statistically different from the control and / or single drug.

[0142] A "therapeutically effective amount" of an agent (e.g., a pharmaceutical composition) refers to an amount effective, at dosages and for periods of time, to achieve the desired therapeutic or preventive result. For example, a therapeutically effective amount of an agent eliminates, alleviates / reduces, delays, minimizes or prevents the adverse effects of a disease.

[0143] An "individual" or "subject" is a mammal. Mammals include, but are not limited to, domesticated animals (e.g., cattle, sheep, cats, dogs, and horses), primates (e.g., humans and non-human primates such as monkeys), rabbits, and rodents (e.g., mice and rats). Specifically, the individual or subject is a human.

[0144] The term "pharmaceutical composition" refers to a preparation that is in such form as to permit the biological activity of the active ingredient contained therein to be effective, and which contains no additional ingredients that are unacceptably toxic to a subject to which the formulation would be administered.

[0145] "Pharmaceutically acceptable carrier" refers to a component of a pharmaceutical composition other than the active ingredient that is non-toxic to the subject. Pharmaceutically acceptable excipients include, but are not limited to, buffers, stabilizers, or preservatives.

[0146] The term "package insert" is used to refer to instructions customarily included in commercial packages of therapeutic products, that contain information about the indications, usage, dosage, administration, combination therapy, contraindications and / or warnings concerning the use of such therapeutic products.

[0147] As used herein, "treatment" refers to clinical intervention that attempts to alter the natural course of the individual being treated, and can be performed either for prevention or in the course of clinical pathology. Desired effects of treatment include, but are not limited to, preventing the onset or recurrence of disease, alleviating symptoms, diminishing any direct or indirect pathological consequences of disease, preventing metastasis, slowing the rate of disease progression, ameliorating or palliating the disease state, and regression or improved prognosis. In some embodiments, the molecules of the invention are used to delay the onset of disease or slow the progression of disease.

[0148] The terms "cancer" and "cancerous" refer to or describe a physiological condition in mammals that is typically characterized by unregulated cell growth, i.e., a proliferative disease, such as a solid tumor or melanoma. A "tumor" contains one or more cancerous cells. As used herein, the term "solid tumor" refers to an abnormal mass of tissue that does not typically contain cysts or fluid areas. Solid tumors can be benign or malignant. Examples of cancer include, but are not limited to, carcinomas, lymphomas, blastomas, sarcomas, and leukemias or lymphoid malignancies. More specific examples of such cancers include breast cancer, squamous cell carcinoma (e.g., epithelial squamous cell carcinoma), lung cancer (including small cell lung cancer, non-small cell lung cancer ("NSCLC"), lung adenocarcinoma and lung squamous cell carcinoma), peritoneal cancer, hepatocellular carcinoma, gastric cancer or stomach cancer (including gastrointestinal cancer), pancreatic cancer, glioblastoma, cervical cancer, ovarian cancer, liver cancer, bladder cancer, hepatoma, colon cancer, rectal cancer, colorectal cancer, endometrial cancer or uterine cancer, salivary gland cancer, kidney cancer or renal cancer, prostate cancer, vulvar cancer, thyroid cancer, liver cancer, anal cancer, penile cancer, and head and neck cancer. In a preferred embodiment, the cancer is breast cancer. In another preferred embodiment, the cancer is gastric cancer.

[0149] The reference to a tumor or cancer as "Stage 0," "Stage I," "Stage II," "Stage III," or "Stage IV," and the various substages within this classification indicate that the tumor or cancer is classified using the Overall Stage Grouping or Roman Numeral Staging method known in the art. Although the actual stage of a cancer depends on the type of cancer, in general, Stage 0 cancers are in situ lesions, Stage I cancers are small localized tumors, Stage II and III cancers are locally advanced tumors that exhibit local lymph node involvement, and Stage IV cancers represent metastatic cancers. The specific stage of each type of tumor is known to the skilled physician.

[0150] The term "metastatic breast cancer" refers to a condition of breast cancer in which cancer cells spread from an initial site through blood or lymphatic vessels to one or more sites elsewhere in the body to form one or more secondary tumors in one or more organs outside the breast.

[0151] "Late" cancer is a cancer that has spread outside the site or organ of origin by local invasion or metastasis. Thus, the term "late" cancer includes both locally advanced and metastatic disease. "Refractory" cancer is a cancer that progresses even if anti-tumor agents, such as chemotherapy, are administered to cancer patients. An example of a refractory cancer is a platinum-refractory cancer. "Recurrent" cancer is a cancer that has regrown at the initial site or at a distal site in response to initial therapy, such as after surgery. "Locally recurrent" cancer is a cancer that recurs after treatment in the same location as a previously treated cancer. "Operable" or "resectable" cancer is a cancer that is confined to the primary organ and is suitable for surgery (resection). "Non-resectable" or "unresectable" cancer cannot be removed (resected) by surgery.

[0152] A cancer or biological sample that "exhibits HER expression, amplification or activation" is one that expresses (including overexpresses) a HER receptor, has an amplified HER gene, and / or otherwise demonstrates activation or phosphorylation of a HER receptor in a diagnostic test.

[0153] The terms "HER-2 positive" and "HER-2 expressivity" are used interchangeably herein. "HER-2 positive" cancers include cancer cells with higher than normal HER-2 levels. Examples of HER-2 positive cancers include HER-2 positive breast cancer and HER2 positive gastric cancer. Optionally, HER-2 positive cancers are HER-2 overexpressing cancers, and in certain embodiments, HER-2 positive cancers have an immunohistochemistry (IHC) score of 2+ or 3+ and / or an in situ hybridization (ISH) amplification ratio of ≥2.0.

[0154] In situ hybridization (ISH) uses a DNA probe coupled to a fluorescent, chromogenic, or silver detection system (i.e., FISH, CISH, or SISH), or a combination of CISH and SISH systems (bright field dual ISH (BDISH) or dual hapten, dual color ISH (DDISH)) to determine the number of her2 copies. ISH can be performed using a single probe to enumerate only the her2 copies of each nucleus, or as a dual probe technique, in which hybridization of a chromosome 17 centromere probe (chromosome enumeration probe 17, CEP17) allows determination of the her2:CEP17 ratio. The two-probe approach can be implemented as a dual color technique (co-hybridization of two probes on the same slide) or as a monochrome assay (using each probe on a continuous slide). The her2:CEP17 ratio is sometimes considered to reflect the her2 amplification status better than the mean her2 copy number, because the mean her2 copy number also depends on other parameters, such as the mitotic index of the tumor, the thickness of the slice, the effect of nuclear truncation, and the abnormal chromosome copy number (aneusomy). The phrase "an in situ hybridization (ISH) amplification ratio of ≥2.0" refers to a her2:CEP17 ratio of ≥2.0. For more details, see, e.g., Sauter G, et al. Guidelines for human epidermal growth factor receptor 2 testing: biologic and methodologic considerations. J Clin Oncol 2009; 27: 1323-1333, and review Hanna et al. Modern Pathology (2014) 27, 4-18.

[0155] In this context, a "patient" or "subject" is a human patient. The patient may be a "cancer patient", ie a patient suffering from or at risk of suffering from one or more symptoms of cancer, particularly gastric cancer or breast cancer.

[0156] A "patient population" refers to a group of cancer patients. Such a population can be used to demonstrate statistically significant efficacy and / or safety of a drug, such as Pertuzumab. A "relapsed" patient is a patient with signs or symptoms of cancer after regression. Optionally, the patient has relapsed after adjuvant or neoadjuvant therapy.

[0157] "Neoadjuvant therapy" or "preoperative therapy" herein refers to therapy given before surgery. The purpose of neoadjuvant therapy is to provide immediate systemic therapy, thereby potentially eradicating micrometastases that would otherwise proliferate when following the standard sequence of surgery followed by systemic therapy. Neoadjuvant therapy can also help reduce tumor size, thereby allowing complete resection of an initially unresectable tumor or preserving a portion of the organ and its function. In addition, neoadjuvant therapy allows for in vivo evaluation of drug efficacy, which can guide the selection of subsequent treatments.

[0158] "Adjuvant therapy" as used herein refers to therapy given after definitive surgery (in which no evidence of residual disease can be detected) to reduce the risk of disease recurrence. The goal of adjuvant therapy is to prevent cancer recurrence and, therefore, reduce the chance of cancer-related death. Adjuvant therapy as used herein specifically excludes neoadjuvant therapy.

[0159] "Chemotherapy" is the use of chemotherapeutic agents useful in treating cancer.

[0160] "Chemotherapeutic agent" refers to a chemical compound that can be used to treat cancer, regardless of the mechanism of action. Classes of chemotherapeutic agents include, but are not limited to, alkylating agents, antimetabolites, spindle poison plant alkaloids, cytotoxic / antitumor antibiotics, topoisomerase inhibitors, antibodies, photosensitizers, and kinase inhibitors.

[0161] "CD20" refers to the B lymphocyte antigen CD20, also known as the B lymphocyte surface antigen B1 or the leukocyte surface antigen Leu-16, and includes any native CD20 from any vertebrate source, including mammals, such as primates (e.g., humans), non-human primates (e.g., cynomolgus monkeys) and rodents (e.g., mice and rats), unless otherwise indicated. The amino acid sequence of human CD20 is shown in Uniprot accession number P11836 (version 149, SEQ ID NO: 85). CD20 is a hydrophobic transmembrane protein with a molecular weight of approximately 35 kD, expressed on pre-B and mature B lymphocytes. The corresponding human gene is transmembrane 4 domains, subfamily A, member 1, also known as MS4A1. This gene encodes a member of the transmembrane 4A gene family. Members of this new protein family are characterized by common structural features and similar intron / exon splicing boundaries and display unique expression patterns between hematopoietic cells and non-lymphoid tissues. This gene encodes a B lymphocyte surface molecule that plays a role in B cell development and differentiation into plasma cells. This family member is located at 11q12 among a cluster of family members. Alternative splicing of this gene produces two transcript variants encoding the same protein. The term "CD20" encompasses "full-length," unprocessed CD20 as well as any form of CD20 derived from processing in cells. The term also encompasses naturally occurring variants of CD20, such as splice variants or allelic variants.

[0162] The terms "anti-CD20 antibody" and "antibody that binds to CD20" refer to an antibody that is capable of binding to CD20 with sufficient affinity such that the antibody can be used as a diagnostic and / or therapeutic agent in targeting CD20. In one embodiment, the extent of binding of the anti-CD20 antibody to an unrelated, non-CD20 protein is less than about 10% of the binding of the antibody to CD20, as measured, for example, by radioimmunoassay (RIA). In certain embodiments, the antibody that binds to CD20 has a binding affinity of ≤1 μM, ≤100 nM, ≤10 nM, ≤1 nM, ≤0.1 nM, ≤0.01 nM, or ≤0.001 nM (e.g., 10 -8 M or less, e.g. 10 -8 M to 10 -13 M, for example 10 -9 M to 10 -13 In certain embodiments, the anti-CD20 antibody binds to a CD20 epitope that is conserved among CD20 from different species.

[0163] "Type II anti-CD20 antibody" means an anti-CD20 antibody having the binding properties and biological activity of the type II anti-CD20 antibody described in Cragg et al., Blood 103 (2004) 2738-2743; Cragg et al., Blood 101 (2003) 1045-1052; Klein et al., mAbs 5 (2013), 22-33. The type II anti-CD20 antibody binds to the class II epitope on CD20, does not localize CD20 to lipid rafts, exhibits ADCC activity, but low CDC (if it is an IgG1 isotype antibody), has less ability to bind to B cells than antibodies that bind to class I CD20 epitopes, exhibits homotypic aggregation and strong death induction. Examples of type II anti-CD20 antibodies include, for example, obinutuzumab (GA101), tositumumab (B1), humanized B-Ly1 antibody IgG1 (a chimeric humanized IgG1 antibody, as disclosed in WO2005 / 044859), 11B8 IgG1 (as disclosed in WO 2004 / 035607) and AT80 IgG1. In a specific aspect, the type II anti-CD20 antibody is obinutuzumab (recommended INN, WHO drug information, Vol. 26, No. 4, 2012, p. 453). As used herein, obinutuzumab is synonymous with GA101. The trade name is or This replaces all previous forms (e.g. Vol. 25, No. 1, 2011, p. 75-76), and was previously known as afutuzumab (Recommended INN, WHO Drug Information, Vol. 23, No. 2, 2009, p. 176; Vol. 22, No. 2, 2008, p. 124). In one aspect, the type II anti-CD20 antibody is tositumomab.

[0164] Exemplary 4-1BB agonists for use in the present invention

[0165] The present invention relates to 4-1BB agonists and their use in combination with HER-2 targeted therapy, particularly their use in a method for treating cancer or delaying cancer progression. In some embodiments, 4-1BB agonists and their use in combination with HER-2 targeted therapy are in a method for treating solid tumors or delaying solid tumor progression.

[0166] In particular, the 4-1BB agonist used in combination with HER-2 targeted therapy is a molecule comprising 4-1BBL. In particular, the 4-1BB agonist used in the present invention comprises three 4-1BBL ectodomains or fragments thereof.

[0167] In a specific aspect, the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

[0168] 4-1BB agonists are particularly useful if it includes an antigen binding domain specific to a target on a tumor-associated antigen, particularly a cancer cell or in a matrix. Thus, in a particular aspect, a 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specifically binding to fibroblast activation protein (FAP) or CEA.

[0169] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises (a) a heavy chain variable region (V H FAP and light chain variable region (V L FAP, heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) a heavy chain variable region (V H FAP and light chain variable region (V L FAP, heavy chain variable region (V HFAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0170] In one specific aspect, the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP and light chain variable region (V L FAP, heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, a light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0171] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L More specifically, the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).

[0172] In another aspect, 4-1BB agonists are antigen binding molecules further comprising the Fc domains consisting of the first and second subunits capable of stabilizing the combination. In one aspect, 4-1BB agonists are antigen binding molecules comprising IgG Fc domains, specifically IgG1 Fc domains or IgG4 Fc domains. In particular, 4-1BB agonists are antigen binding molecules comprising one or more places that reduce the binding to Fc receptors and / or the amino acid substitutions of effector functions. In a specific aspect, 4-1BB agonists are antigen binding molecules comprising IgG1 Fc domains comprising amino acid substitutions L234A, L235A and P329G.

[0173] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:

[0174] (a) at least one antigen binding domain that is capable of specifically binding to FAP, and

[0175] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0176] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0177] In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0178] (a) at least one Fab domain capable of specifically binding to FAP, and

[0179] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0180] The antigen binding molecule is characterized by

[0181] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0182] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL ectodomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL ectodomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0183] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to the VH or VL via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of the polypeptide via a peptide linker.

[0184] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0185] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 H FAP) and a light chain variable region (V L FAP) comprising the amino acid sequence of SEQ ID NO: 24 L FAP), and

[0186] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0187] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0188] In a specific aspect, the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:

[0189] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:41, a first light chain comprising the amino acid sequence of SEQ ID NO:42, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and

[0190] b) A molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, a first light chain comprising the amino acid sequence of SEQ ID NO:46, a second heavy chain comprising the amino acid sequence of SEQ ID NO:47 and a second light chain comprising the amino acid sequence of SEQ ID NO:48.

[0191] In particular, the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 41, a first light chain comprising the amino acid sequence of SEQ ID NO: 42, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 43, and a second light chain comprising the amino acid sequence of SEQ ID NO: 44.

[0192] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0193] (a) at least one antigen binding domain that is capable of specifically binding to FAP, and

[0194] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0195] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:

[0196] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0197] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0198] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0199] Particular bispecific antibodies are described in PCT Publication No. WO 2016 / 075278 A1 or PCT Publication No. WO 2016 / 156291 A1.

[0200] In yet another aspect, the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0201] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises a heavy chain variable region (V H CEA and light chain variable region (V L CEA, heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, a light chain variable region (V L CEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0202] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0203] In another aspect, 4-1BB agonists are antigen binding molecules further comprising the Fc domains consisting of the first and second subunits capable of stabilizing the combination. In one aspect, 4-1BB agonists are antigen binding molecules comprising IgG Fc domains, specifically IgG1 Fc domains or IgG4 Fc domains. In particular, 4-1BB agonists are antigen binding molecules comprising one or more places that reduce the binding to Fc receptors and / or the amino acid substitutions of effector functions. In a specific aspect, 4-1BB agonists are antigen binding molecules comprising IgG1 Fc domains comprising amino acid substitutions L234A, L235A and P329G.

[0204] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:

[0205] (a) at least one antigen binding domain capable of specifically binding to CEA, and

[0206] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0207] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0208] In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0209] (a) at least one Fab domain capable of specifically binding to CEA, and

[0210] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0211] The antigen binding molecule is characterized by

[0212] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0213] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL ectodomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL ectodomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0214] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to the VH or VL via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of the polypeptide via a peptide linker.

[0215] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0216] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0217] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0218] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0219] In a specific aspect, the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO: 41, a first light chain comprising the amino acid sequence of SEQ ID NO: 42, a second heavy chain comprising the amino acid sequence of SEQ ID NO: 82, and a second light chain comprising the amino acid sequence of SEQ ID NO: 83.

[0220] In another aspect, the 4-1BB agonist is an antigen binding molecule comprising:

[0221] (a) at least one antigen binding domain capable of specifically binding to CEA, and

[0222] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0223] In one aspect, a 4-1BB agonist is an antigen binding molecule comprising:

[0224] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0225] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0226] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein a polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0227] In yet another aspect, the 4-1BB agonist comprises an anti-CEA / anti-4-1BB bispecific antibody.

[0228] Agents targeting HER-2

[0229] In various aspects of the invention, the 4-1BB agonists described herein are used in combination with HER-2 targeted therapies.

[0230] In some aspects of the invention, a 4-1BB agonist is used in combination with a HER-2 targeting agent. In some embodiments, the agent interacts with HER-2. In some embodiments, the agent is a HER-2 antagonist. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody, a bispecific HER-2 antibody and / or a HER-2 antibody-drug conjugate. In some embodiments, the agent is an antibody or an antigen-binding fragment, particularly an anti-HER-2 antibody. In some embodiments, the agent is a bispecific HER-2 antibody. In some embodiments, the agent is an antibody-drug conjugate.

[0231] In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and magetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0232] In some aspects, the HER-2 targeting agent comprises an antibody comprising a heavy chain variable domain (VH) of SEQ ID NO: 96 and a light chain variable domain (VL) of SEQ ID NO: 97. In some aspects, the HER-2 targeting agent comprises an antibody comprising a heavy chain variable domain (VH) of SEQ ID NO: 98 and a light chain variable domain (VL) of SEQ ID NO: 99.

[0233] In some embodiments, and for any of the uses described herein, the medicament comprises trastuzumab (CAS 180288-69-1, huMAb4D5-8, rhuMAb HER2, Genentech), pertuzumab (rhuMAb 2C4, Genentech, Inc, South San Francisco) or trastuzumab emtansine (trastuzumab-MCC-DM1, T-DM1, ado-trastuzumab emtansine, ). In some embodiments, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some embodiments, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some embodiments, the HER-2 targeting agent comprises or consists of a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some embodiments, the HER-2 targeting agent comprises or consists of a combination of trastuzumab and pertuzumab. More particularly, the agent is trastuzumab.

[0234] Trastuzumab is a recombinant DNA derived, IgG1κ monoclonal antibody that is a humanized version of the murine anti-HER-2 antibody (4D5) that selectively binds to the extracellular domain of HER-2 with high affinity (Kd=5 nM) in a cell-based assay. Trastuzumab is an antibody having antigen-binding residues of or derived from the murine 4D5 antibody (ATCC CRL 10463, deposited on May 24, 1990 at the American Type Culture Collection, 12301 Parklawn Drive, Rockville, Md. 20852, under the Budapest Treaty). Exemplary humanized 4D5 antibodies include huMAb4D5-1, huMAb4D5-2, huMAb4D5-3, huMAb4D5-4, huMAb4D5-5, huMAb4D5-6, huMAb4D5-7, and huMAb4D5-8 As in US 5821337.

[0235] Pertuzumab is a recombinant humanized monoclonal antibody generated based on the human IgG1 (κ) framework, see, for example, US7560111. Pertuzumab differs from trastuzumab in the epitope binding regions of the light chain (12 amino acid differences) and the heavy chain (30 amino acid differences). As a result of these differences, Pertuzumab binds to completely different epitopes on the HER2 receptor. Pertuzumab's binding to the HER2 receptor on human epithelial cells prevents it from forming a complex with other members of the HER receptor family (Agus et al., Cancer Cell 2: 127-137 (2002)). By blocking complex formation, Pertuzumab prevents the growth stimulating effects of ligands on the complex (e.g., EGF and heregulin).

[0236] Trastuzumab emtansine is an antibody-drug conjugate in which trastuzumab is connected to a maytansine alkaloid drug module DM1 via a linker module MCC (US 5208020; US 6441163). The drug-to-antibody ratio or drug load ranges from an integer value of 1 to about 8. Trastuzumab-MCC-DM1 includes all mixtures of various loaded and attached antibody-drug conjugates, wherein 1, 2, 3, 4, 5, 6, 7, and 8 drug modules are covalently attached to the antibody trastuzumab (US 7097840; US 2005 / 0276812; US2005 / 0166993). The average drug load is about 3.5.

[0237] Trastuzumab, Pertuzumab, and Trastuzumab emtansine may be used in any combination. In some embodiments, the HER-2 targeting agent comprises Trastuzumab and Pertuzumab.

[0238] As used herein, the terms "HER-2 targeted therapy", "HER-2 targeting agent" and "agent interacting with HER-2" refer to one or more agents targeting HER-2 (ErbB2) receptor tyrosine kinase. In particular, the term refers to one or more agents that selectively bind to HER-2. The agent can be an antibody, particularly a monoclonal antibody. In some cases, the agent selectively binds to HER-2 with high affinity, for example, in the nM or pM range. In some cases, the agent binds to the extracellular domain of the HER-2 receptor. The agent can cause: down-regulating HER-2 receptor expression, inhibiting the proliferation of human tumor cells overexpressing HER-2 protein, enhancing immune recruitment and ADCC for tumor cells overexpressing HER-2 protein, and / or down-regulating angiogenesis factors. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. The term "anti-HER-2 antibody" or "antibody that binds to human HER-2" or "antibody that specifically binds to human HER-2" or "antagonist anti-HER2" refers to an antibody that specifically binds to human HER-2. The antibody can bind to human HER-2 antigen with a binding affinity of <10nM, <5nM, <2nM, <1nM, <0.5nM, or a lower Kd value. Binding affinity can be determined using standard binding assays, such as surface plasmon resonance technology ( GE-Healthcare Uppsala, Sweden).

[0239] Preparation of bispecific antibodies for use in the present invention

[0240] In some aspects, the therapeutic agent used in combination comprises a multispecific antibody, such as a bispecific antibody. A multispecific antibody is a monoclonal antibody that has binding specificity for at least two different sites. In some aspects, the binding specificity is for different antigens. In some aspects, the binding specificity is for different epitopes on the same antigen. Bispecific antibodies can be prepared as full-length antibodies or antibody fragments.

[0241] Techniques for producing multispecific antibodies include, but are not limited to, recombinant co-expression of two immunoglobulin heavy chain-light chain pairs with different specificities (see Milstein and Cuello, Nature, 305:537 (1983)), WO 93 / 08829, and Traunecker et al., EMBO J. 10:3655 (1991)), and “knob-into-hole” engineering (see, e.g., U.S. Pat. No. 5,731,168). It can also be achieved by engineering electrostatic manipulation effects for generating antibody Fc-heterodimer molecules (WO 2009 / 089004A1); cross-linking two or more antibodies or fragments (see, e.g., U.S. Pat. No. 4,676,980, and Brennan et al., Science, 229:81 (1985)); using leucine zippers to generate bispecific antibodies (see, e.g., Kostelny et al., J. Immunol., 148(5):1547-1553 (1992)); using "diabody" technology for generating bispecific antibody fragments (see, e.g., Hollinger et al., Proc. Natl. Acad. Sci. USA, 90:6444-6448 (1993)); and using single-chain Fv (sFv) dimers (see, e.g., Gruber et al., 2003). al., J. Immunol., 152:5368 (1994)); and trispecific antibodies are prepared to generate multispecific antibodies as described, for example, in Tutt et al., J. Immunol. 147:60 (1991).

[0242] Also included herein are engineered antibodies having three or more functional antigen binding sites, including "octopus antibodies" (see, e.g., US 2006 / 0025576 A1).

[0243] The antibodies or fragments herein also include "dual-acting FAbs" or "DAFs" comprising antigen binding sites that bind to two different antigens (see, e.g., US2008 / 0069820). Also included herein are "Crossmab" antibodies (see, e.g., WO2009 / 080251, WO2009 / 080252, WO2009 / 080253, or WO2009 / 080254).

[0244] Another technology used to generate bispecific antibody fragments is the "bispecific T cell engager" or The present invention relates to a method for producing antibody-binding proteins (see, for example, WO2004 / 106381, WO2005 / 061547, WO2007 / 042261, and WO2008 / 119567). This method utilizes two antibody variable domains arranged on a single polypeptide. For example, a single polypeptide chain includes two single-chain Fv (scFv) fragments, each having a variable heavy chain (V) separated by a polypeptide linker. H ) domain and a variable light chain (V L ) domains, the length of the polypeptide linker being sufficient to allow intramolecular association between the two domains. The single polypeptide further comprises a polypeptide spacer sequence between the two scFv fragments. Each scFv recognizes a different epitope, and these epitopes can be specific for different cell types, such that cells of two different cell types come into close proximity or tethering when each scFv engages its cognate epitope. A specific embodiment of this approach comprises a scFv that recognizes a cell surface antigen expressed by an immune cell (e.g., a CD3 polypeptide on a T cell) joined to another scFv that recognizes a cell surface antigen expressed by a target cell (such as a malignant or tumor cell).

[0245] Because it is a single polypeptide, the bispecific T cell adapter can be expressed using any prokaryotic or eukaryotic cell expression system known in the art (e.g., CHO cell line). However, specific purification techniques (see, e.g., EP1691833) may be necessary to separate monomeric bispecific T cell adapters from other polymeric species (which may have biological activities different from the predetermined activity of the monomer). In an exemplary purification scheme, a solution containing a secreted polypeptide is first subjected to metal affinity chromatography, and the polypeptide is eluted with a gradient of imidazole concentration. This eluate is further purified using anion exchange chromatography, and the polypeptide is eluted with a gradient of sodium chloride concentration. Finally, size exclusion chromatography is performed on this eluate to separate monomeric and polymeric species. In one aspect, the bispecific bispecific antibody used in the present invention is composed of a single polypeptide chain comprising two single-chain Fv fragments (scFV) fused to each other by a peptide linker.

[0246] Fc domain modifications that reduce Fc receptor binding and / or effector function

[0247] The Fc domains of the antigen binding molecules of the present invention are composed of a pair of polypeptide chains comprising the heavy chain domains of immunoglobulin molecules. For example, the Fc domains of immunoglobulin G (IgG) molecules are dimers, each of which subunits comprises CH2 and CH3 IgG heavy chain constant domains. The two subunits of the Fc domains can stably associate with each other.

[0248] The Fc domain confers favorable pharmacokinetic properties to the antigen binding molecules of the present invention, including a long serum half-life and a favorable tissue-blood distribution ratio that contribute to good accumulation in target tissues. However, at the same time, this may result in unwanted targeting of the bispecific antibodies of the present invention to cells expressing Fc receptors rather than preferred antigen-carrying cells. Thus, in a particular aspect, compared with the native IgG1 Fc domain, the Fc domain of the antigen binding molecule of the present invention exhibits reduced binding affinity to Fc receptors and / or reduced effector functions. In one aspect, Fc does not substantially bind to Fc receptors and / or does not induce effector functions. In a particular aspect, the Fc receptor is an Fcγ receptor. In one aspect, the Fc receptor is a human Fc receptor. In a specific aspect, the Fc receptor is an activating human Fcγ receptor, more specifically human FcγRIIIa, FcγRI or FcγRIIa, most specifically human FcγRIIIa. In one aspect, the Fc domain does not induce effector functions. Reduced effector function may include, but is not limited to, one or more of the following: reduced complement dependent cytotoxicity (CDC), reduced antibody-dependent cell-mediated cytotoxicity (ADCC), reduced antibody-dependent cellular phagocytosis (ADCP), reduced cytokine secretion, reduced immune complex-mediated uptake of antigen by antigen presenting cells, reduced binding to NK cells, reduced binding to macrophages, reduced binding to monocytes, reduced binding to polymorphonuclear cells, reduced direct signaling that induces apoptosis, reduced dendritic cell maturation, or reduced T cell priming.

[0249] In certain aspects, one or more amino acid modifications can be introduced into the Fc region of an antibody provided herein, thereby generating an Fc region variant. The Fc region variant may comprise a human Fc region sequence (e.g., human IgG1, IgG2, IgG3 or IgG4 Fc region) comprising an amino acid modification (e.g., substitution) at one or more amino acid positions.

[0250] In a specific aspect, the invention provides an antibody, wherein the Fc domain comprises one or more amino acid substitutions that reduce binding to an Fc receptor, particularly an Fcγ receptor.

[0251] In one aspect, the Fc domain of the antibody of the present invention comprises one or more amino acid mutations that reduce the binding affinity of the Fc domain to Fc receptors and / or effector function. Typically, the same one or more amino acid mutations are present in each of the two subunits of the Fc domain. In particular, the Fc domain comprises amino acid substitutions at positions E233, L234, L235, N297, P331 and P329 (EU numbering). In particular, the Fc domain comprises amino acid substitutions at positions 234 and 235 (EU numbering) and / or 329 (EU numbering) of the IgG heavy chain. More particularly, provided is an antibody according to the present invention, comprising an Fc domain with amino acid substitutions L234A, L235A and P329G ("P329G LALA", EU numbering) in the IgG heavy chain. Amino acid substitutions L234A and L235A refer to so-called LALA mutations. The "P329G LALA" amino acid substitution combination almost completely eliminates Fcγ receptor binding of human IgG1 Fc domains and is described in International Patent Application Publication No. WO 2012 / 130831 A1, which also describes methods for making such mutant Fc domains and methods for determining their properties such as Fc receptor binding or effector function.

[0252] Fc domains with reduced Fc receptor binding and / or effector function also include those with substitutions of one or more Fc domain residues 238, 265, 269, 270, 297, 327 and 329 (U.S. Pat. No. 6,737,056). Such Fc mutants include Fc mutants with substitutions at two or more amino acid positions 265, 269, 270, 297 and 327, including the so-called "DANA" Fc mutant with substitutions of residues 265 and 297 becoming alanine (U.S. Pat. No. 7,332,581).

[0253] In another aspect, the Fc domain is an IgG4 Fc domain. Compared with IgG1 antibodies, IgG4 antibodies exhibit reduced binding affinity to Fc receptors and reduced effector functions. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions at position S228 (Kabat numbering), particularly amino acid substitutions S228P. In a more specific aspect, the Fc domain is an IgG4 Fc domain comprising amino acid substitutions L235E and S228P and P329G (EU numbering). Such IgG4 Fc domain mutants and their Fcγ receptor binding properties are also described in WO 2012 / 130831.

[0254] Mutant Fc domains can be prepared by amino acid deletion, substitution, insertion or modification using genetic or chemical methods known in the art. Genetic methods can include site-specific mutagenesis of the encoding DNA sequence, PCR, gene synthesis, etc. The correct nucleotide changes can be verified, for example, by sequencing.

[0255] Binding to Fc receptors can be readily determined, for example, by ELISA or by surface plasmon resonance (SPR) using standard instrumentation such as a BIAcore instrument (GE Healthcare), and Fc receptors such as those obtainable by recombinant expression. Alternatively, the binding affinity of an Fc domain or a cell-activating antibody comprising an Fc domain to an Fc receptor can be assessed using a cell line known to express a specific Fc receptor, such as human NK cells expressing the FcγIIIa receptor.

[0256] The effector function of the Fc domain or the antibody of the present invention comprising the Fc domain can be measured by methods known in the art. A suitable assay for measuring ADCC is described herein. Other examples of in vitro assays for assessing ADCC activity of molecules of interest are described in U.S. Pat. No. 5,500,362; Hellstrom et al., Proc Natl Acad Sci USA 83, 7059-7063 (1986) and Hellstrom et al., Proc Natl Acad Sci USA 82, 1499-1502 (1985); U.S. Pat. No. 5,821,337; Bruggemann et al., J Exp Med 166, 1351-1361 (1987). Alternatively, a non-radioactive assay method can be used (see, for example, ACTI TM non-radioactive cytotoxicity assay for flow cytometry (Cell Technology, Inc., Mountain View, CA); and Non-radioactive cytotoxicity assay (Promega, Madison, WI). Useful effector cells for such assays include peripheral blood mononuclear cells (PBMC) and natural killer (NK) cells. Alternatively or additionally, ADCC activity of the molecule of interest can be assessed in vivo, for example in an animal model, such as that disclosed in Clynes et al., Proc Natl Acad Sci USA 95, 652-656 (1998).

[0257] In some aspects, the binding of the Fc domain to complement components, specifically C1q, is reduced. Thus, in some embodiments in which the Fc domain is engineered to have reduced effector function, the reduced effector function comprises reduced CDC. A C1q binding assay can be performed to determine whether the bispecific antibodies of the invention are able to bind to C1q and therefore have CDC activity (see, e.g., C1q and C3c binding ELISA in WO 2006 / 029879 and WO 2005 / 100402). To assess complement activation, a CDC assay can be performed (see, e.g., Gazzano-Santoro et al., J Immunol Methods 202, 163 (1996); Cragg et al., Blood 101, 1045-1052 (2003); and Cragg and Glennie, Blood 103, 2738-2743 (2004)).

[0258] Fc domain modifications that promote heterodimerization

[0259] The bispecific antigen binding molecule of the present invention comprises one of the two subunits in the Fc domain or another different antigen binding sites fused, so that the two subunits in the Fc domain can be included in two non-identical polypeptide chains. The recombinant coexpression of these polypeptides and subsequent dimerization result in several possible combinations of two polypeptides. In order to improve the productivity and purity of the bispecific antibody of the present invention in the recombinant generation, it would be advantageous to introduce the combined modification of the polypeptide that promotes the desired polypeptide in the Fc domain of the bispecific antigen binding molecule of the present invention.

[0260] Thus, in a particular aspect, the present invention relates to a bispecific antigen binding molecule comprising (a) at least one antigen binding domain capable of specifically binding to a tumor associated antigen,

[0261] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0262] wherein the antigen binding molecule is characterized in that the first polypeptide comprises two extracellular domains of 4-1BBL or two fragments thereof connected to each other via a peptide linker and in that the second polypeptide comprises only one extracellular domain of said 4-BBL or a fragment thereof, and

[0263] (c) An Fc domain consisting of a first and a second subunit capable of stably combining, wherein the Fc domain comprises a modification that promotes the combination of the first and second subunits of the Fc domain. The site of the most extensive protein-protein interaction between the two subunits of the human IgG Fc domain is in the CH3 domain of the Fc domain. Thus, in one aspect, the modification is in the CH3 domain of the Fc domain.

[0264] In a specific aspect, the modification is a so-called "knob-into-hole" modification, comprising a "knob" modification in one of the two subunits of the Fc domain and a "hole" modification in the other of the two subunits of the Fc domain. Thus, the present invention relates to an antigen binding molecule comprising (a) at least one antigen binding domain capable of specifically binding to a tumor-associated antigen, (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL outer domains or two fragments thereof connected to each other by a peptide linker and that the second polypeptide comprises only one 4-1BBL outer domain or a fragment thereof, and (c) an Fc domain consisting of the first and second subunits capable of stably combining, wherein according to the knob-into-hole method, the first subunit of the Fc domain comprises a knob and the second subunit of the Fc domain comprises a hole. In a specific aspect, the first subunit of the Fc domain comprises amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises amino acid substitutions Y349C, T366S and Y407V (numbering according to the Kabat EU index).

[0265] The "knob-into-hole" technique is described in, for example, US 5,731,168; US 7,695,936; Ridgway et al., Prot Eng 9, 617-621 (1996) and Carter, J Immunol Meth 248, 7-15 (2001). Generally, the method involves introducing a protuberance ("knob") at the interface of a first polypeptide and introducing a corresponding cavity ("hole") in the interface of a second polypeptide, so that the protuberance can be placed in the cavity, thereby promoting heterodimer formation and hindering homodimer formation. The protuberance is constructed by replacing a small amino acid side chain from the interface of the first polypeptide with a larger side chain (e.g., tyrosine or tryptophan). A compensatory cavity of the same or similar size as the protuberance is created in the interface of the second polypeptide by replacing a large amino acid side chain with a smaller side chain (e.g., alanine or threonine).

[0266] Thus, in one aspect, in the CH3 domains of the first subunit of the Fc domains of the bispecific antigen binding molecule of the present invention, amino acid residues are replaced with amino acid residues with larger side chain volume, thereby generating a protuberance in the CH3 domains of the first subunit, which can be placed in the cavity in the CH3 domains of the second subunit, and in the CH3 domains of the second subunit of the Fc domains, amino acid residues are replaced with amino acid residues with smaller side chain volume, thereby generating a cavity in the CH3 domains of the second subunit, in which the protuberance in the CH3 domains of the first subunit can be placed. Protuberances and cavities can be generated by changing the nucleic acid encoding the polypeptide, for example, by site-specific mutagenesis, or by peptide synthesis. In a specific aspect, the threonine residue at position 366 is replaced with a tryptophan residue (T366W) in the CH3 domains of the first subunit of the Fc domains, and the tyrosine residue at position 407 is replaced with a valine residue (Y407V) in the CH3 domains of the second subunit of the Fc domains. In one aspect, the threonine residue at position 366 is additionally replaced with a serine residue (T366S) and the leucine residue at position 368 is replaced with an alanine residue (L368A) in the second subunit of the Fc domain.

[0267] In yet another aspect, the serine residue at position 354 is replaced with a cysteine ​​residue in the first subunit of the Fc domain (S354C), and the tyrosine residue at position 349 is replaced with a cysteine ​​residue in the second subunit of the Fc domain (Y349C). The introduction of these two cysteine ​​residues results in the formation of a further stabilizing disulfide bridge (Carter, J Immunol Methods 248, 7-15 (2001)) of the dimer between the two subunits of the Fc domain. In a specific aspect, the first subunit of the Fc domain comprises amino acid substitutions S354C and T366W (EU numbering) and the second subunit of the Fc domain comprises amino acid substitutions Y349C, T366S and Y407V (numbering according to Kabat EU index).

[0268] In an alternative aspect, modifications that promote association of the first and second subunits of the Fc domain include modifications that mediate electrostatic manipulation effects, such as described in PCT Publication WO 2009 / 089004. Generally, this approach involves replacing one or more amino acid residues at the interface of the two Fc domain subunits with charged amino acid residues such that homodimer formation becomes electrostatically unfavorable but heterodimerization is electrostatically favorable.

[0269] The C-terminus of the heavy chain of the bispecific antibody reported herein can be a complete C-terminus ending with amino acid residue PGK. The C-terminus of the heavy chain can be a shortened C-terminus in which one or two C-terminal amino acid residues have been removed. In a preferred aspect, the C-terminus of the heavy chain is a shortened C-terminus ending with PG. In one aspect of all aspects reported herein, the bispecific antibody comprising a heavy chain including C-terminal CH3 domains specified herein comprises a C-terminal glycine-lysine dipeptide (G446 and K447, numbering is according to the Kabat EU index). In one embodiment of all aspects reported herein, the bispecific antibody comprising a heavy chain including C-terminal CH3 domains specified herein comprises a C-terminal glycine residue (G446, numbering is according to the Kabat EU index).

[0270] Modifications in the Fab domain

[0271] In one aspect, the present invention relates to an antigen binding molecule containing 4-1BBL, comprising (a) a Fab fragment capable of specifically binding to a tumor-associated antigen, (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL outer domains or two fragments thereof connected to each other by a peptide linker and that the second polypeptide comprises only one 4-1BBL outer domain or a fragment thereof, and (c) an Fc domain consisting of a first and a second subunit capable of stabilizing the association, wherein in one of the Fab fragments, either the variable domains VH and VL or the constant domains CH1 and CL are exchanged. The bispecific antibody is prepared according to the Crossmab technology.

[0272] Multispecific antibodies with domain replacement / exchange in one binding arm (CrossMab VH-VL or CrossMab CH-CL) are described in detail in WO2009 / 080252 and Schaefer, W. et al., PNAS, 108 (2011) 11187-1191. They clearly reduce the side products caused by the mispairing of the light chain against the first antigen with the wrong heavy chain against the second antigen (compared to the approach without such domain exchange).

[0273] In one aspect, the present invention relates to a bispecific antigen-binding molecule comprising (a) a first Fab fragment capable of specifically binding to a tumor-associated antigen, (b) a first and a second polypeptide linked to each other by a disulfide bond, wherein the antigen-binding molecule is characterized in that the first polypeptide comprises two 4-1BBL extracellular domains or two fragments thereof linked to each other by a peptide linker and in that the second polypeptide comprises only one 4-1BBL extracellular domain or a fragment thereof, and wherein each of them is linked to a CH1 or CL domain, and (c) an Fc domain composed of a first and a second subunit capable of stably combining, wherein the constant domains CL and CH1 adjacent to 4-1BBL are replaced with each other so that the CH1 domain is part of the light chain and the CL domain is part of the heavy chain.

[0274] In another aspect, the present invention relates to a bispecific antigen binding molecule, comprising (a) two light chains and two heavy chains of an antibody comprising two Fab fragments and Fc domains capable of specific binding to 4-1BB, and (b) two other Fab fragments capable of specific binding to tumor-associated antigens, wherein each of the other Fab fragments is connected to the C-terminus of the heavy chain of (a) via a peptide linker. In a specific aspect, the other Fab fragment is a Fab fragment, wherein the variable domains VL and VH replace each other so that the VH domain is a part of the light chain and the VL domain is a part of the heavy chain.

[0275] In another aspect, and in order to further improve the correct pairing, comprising (a) a first Fab fragment capable of specific binding to a tumor-associated antigen, (b) a first and a second polypeptide connected to each other by a disulfide bond, wherein the antigen binding molecule is characterized in that the first polypeptide comprises two 4-1BBL outer domains or two fragments thereof connected to each other by a peptide linker and that the second polypeptide comprises only one 4-1BBL outer domain or its fragment, and wherein each of them is connected to a CH1 or CL domain, and (c) the bispecific antigen binding molecule of the Fc domain consisting of the first and second subunits capable of stabilizing the combination may contain amino acid substitutions with different charges (so-called "charged residues"). These modifications are introduced in cross or non-cross CH1 and CL domains. In a specific aspect, the present invention relates to a bispecific antigen binding molecule, wherein the amino acid at position 123 (EU numbering) in one of the CL domains is replaced by arginine (R) and the amino acid at position 124 (EU numbering) is replaced by lysine (K) and wherein the amino acid at position 147 (EU numbering) and position 213 (EU numbering) in one of the CH1 domains is replaced by glutamic acid (E).

[0276] More particularly, the present invention relates to a bispecific binding molecule comprising a Fab, wherein the amino acid at position 123 (EU numbering) in the CL domain adjacent to 4-1BBL is replaced by arginine (R) and the amino acid at position 124 (EU numbering) is replaced by lysine (K), and wherein the amino acids at position 147 (EU numbering) and position 213 (EU numbering) in the CH1 domain adjacent to 4-1BBL are replaced by glutamic acid (E).

[0277] Polynucleotide

[0278] The present invention further provides isolated polynucleotides encoding an antibody or fragment thereof as described herein.

[0279] The isolated polynucleotide encoding the antibody of the present invention can be expressed as a single polynucleotide encoding the entire antigen binding molecule or as a variety of (e.g., two or more) polynucleotides of coexpression. The polypeptide encoded by the coexpressed polynucleotide can be combined to form a functional antigen binding molecule via, for example, a disulfide bond or other means. For example, the light chain portion of an immunoglobulin and the heavy chain portion of an immunoglobulin can be encoded by separate polynucleotides. When coexpressed, the heavy chain polypeptide will be combined with the light chain polypeptide to form an immunoglobulin.

[0280] In some aspects, the isolated polynucleotide encodes the entire antibody according to the invention as described herein. In other embodiments, the isolated polynucleotide encodes a polypeptide contained in an antibody according to the invention as described herein.

[0281] In certain embodiments, the polynucleotide or nucleic acid is DNA. In other embodiments, the polynucleotide of the present invention is RNA, for example in the form of messenger RNA (mRNA). The RNA of the present invention can be single-stranded or double-stranded.

[0282] Recombination methods

[0283] Bispecific antibodies as used in the present invention can be obtained by, for example, solid-state peptide synthesis (e.g., Merrifield solid phase synthesis) or recombinant generation. For recombinant generation, one or more polynucleotides encoding, for example, antibodies or polypeptide fragments thereof as described above are separated and inserted into one or more vectors for further cloning and / or expression in host cells. Such polynucleotides can be easily separated and sequenced using conventional procedures. In one aspect of the present invention, a vector comprising one or more polynucleotides of the present invention is provided, preferably an expression vector. Methods well known to those skilled in the art can be used to construct an expression vector containing the coding sequence of the antibody (fragment) together with suitable transcription / translation control signals. These methods include in vitro recombinant DNA technology, synthetic technology, and in vivo recombination / genetic recombination. See, for example, Maniatis et al., MOLECULAR CLONING: A LABORATORY MANUAL, Cold Spring Harbor Laboratory, NY (1989); and Ausubel et al., CURRENT PROTOCOLS IN MOLECULAR BIOLOGY, Greene Publishing Associates and Wiley Interscience, NY (1989). The expression vector can be a part of a virus, a plasmid, or can be a nucleic acid fragment. The expression vector includes an expression cassette in which a polynucleotide (i.e., a coding region) encoding an antibody or its polypeptide fragment is cloned in operable association with a promoter and / or other transcription or translation control elements. As used herein, a "coding region" is a portion of a nucleic acid consisting of codons that are translated into amino acids. Although "stop codons" (TAG, TGA, or TAA) are not translated into amino acids, if present, it can be considered as a part of the coding region, but any flanking sequences, such as promoters, ribosome binding sites, transcription terminators, introns, 5' and 3' untranslated regions, etc. are not part of the coding region. Two or more coding regions may be present in a single polynucleotide construct, such as on a single vector, or in separate polynucleotide constructs, such as on separate (different) vectors. Moreover, any vector may contain a single coding region, or may contain two or more coding regions, for example, the vector of the present invention may encode one or more polypeptides, which are separated into final proteins after translation or co-translation via proteolytic cleavage. In addition, the vectors, polynucleotides, or nucleic acids of the present invention may encode heterologous coding regions, either fused or unfused to polynucleotides encoding antibodies or polypeptide fragments thereof, or variants or derivatives thereof of the present invention. Heterologous coding regions include, but are not limited to, specialized elements or motifs, such as secretory signal peptides or heterologous functional domains.Operable association is such a way that when a gene product, such as a coding region of a polypeptide, is so associated with one or more regulatory sequences, the expression of the gene product is placed under the influence or control of the regulatory sequences. If the induction of promoter function leads to the transcription of mRNA encoding the desired gene product and if the nature of the connection between the two DNA fragments does not interfere with the ability of the expression regulatory sequence to direct the expression of the gene product or the ability of the DNA template to be transcribed, the two DNA fragments (such as a polypeptide coding region and a promoter associated therewith) are "operably associated". In this way, if the promoter is able to affect the transcription of a nucleic acid encoding a polypeptide, the promoter region and the nucleic acid will be operably associated. The promoter can be a cell-specific promoter that directs substantial transcription of DNA only in a predetermined cell. In addition to the promoter, other transcription control elements, such as enhancers, operator genes, repressors, and transcription termination signals can be operably associated with the polynucleotide to direct cell-specific transcription.

[0284] Suitable promoters and other transcription control regions are disclosed herein. A variety of transcription control regions are known to those skilled in the art. These include, but are not limited to, transcription control regions that function in vertebrate cells, such as, but not limited to, promoters and enhancer segments from cytomegalovirus (e.g., immediate early promoter, together with intron A), simian virus 40 (e.g., early promoter), and retroviruses (such as, for example, Rous sarcoma virus). Other transcription control regions include those derived from vertebrate genes such as actin, heat shock protein, bovine growth hormone, and rabbit alpha globin, as well as other sequences capable of controlling gene expression in eukaryotic cells. Additional suitable transcription control regions include tissue-specific promoters and enhancers and inducible promoters (e.g., tetracycline inducible promoters). Similarly, a variety of translation control elements are known to those of ordinary skill in the art. These include, but are not limited to, ribosome binding sites, translation initiation and termination codons, and elements derived from viral systems (particularly internal ribosome entry sites or IRES, also known as CITE sequences). The expression cassette may also include other features, such as an origin of replication, and / or chromosomal integration elements, such as retroviral long terminal repeats (LTRs), or adeno-associated virus (AAV) inverted terminal repeats (ITRs).

[0285] The polynucleotide and nucleic acid coding regions of the present invention may be combined with additional coding regions encoding secretory or signal peptides (which direct the secretion of the polypeptides encoded by the polynucleotides of the present invention). For example, if it is desired to secrete an antibody or polypeptide fragment thereof, DNA encoding a signal sequence may be placed upstream of the nucleic acid encoding the antibody or polypeptide fragment thereof of the present invention. According to the signal hypothesis, proteins secreted by mammalian cells have a signal peptide or secretory leader sequence that is cleaved from the mature protein once the export of the growing protein chain across the rough endoplasmic reticulum is initiated. Those of ordinary skill in the art know that polypeptides secreted by vertebrate cells generally have a signal peptide fused to the N-terminus of the polypeptide that is cleaved from the translated polypeptide to generate a secreted or "mature" form of the polypeptide. In certain embodiments, a natural signal peptide, such as an immunoglobulin heavy or light chain signal peptide, or a functional derivative of the sequence that retains the ability to direct the secretion of a polypeptide to which it is operably associated is used. Alternatively, a heterologous mammalian signal peptide or a functional derivative thereof may be used. For example, the wild-type leader sequence may be replaced with the leader sequence of human tissue plasminogen activator (TPA) or mouse β-glucuronidase.

[0286] DNA encoding short protein sequences that can be used to facilitate later purification (eg, a histidine tag) or to aid in labeling of the fusion protein may be included within or at the end of a polynucleotide encoding an antibody or polypeptide fragment thereof of the invention.

[0287] In another aspect of the present invention, a host cell comprising one or more polynucleotides of the present invention is provided. In certain embodiments, a host cell comprising one or more vectors of the present invention is provided. Polynucleotides and vectors may be incorporated into any of the features described herein for polynucleotides and vectors, either singly or in combination. In one aspect, the host cell comprises (e.g., has been transformed or transfected) a vector comprising a polynucleotide encoding an antibody (part of) of the present invention. As used herein, the term "host cell" refers to any type of cell system that can be engineered to generate a fusion protein of the present invention or a fragment thereof. Host cells suitable for replication and support for expression of antigen-binding molecules are well known in the art. Such cells can be appropriately transfected or transduced with a specific expression vector, and a large number of cells containing the vector can be cultured for inoculating large-scale fermenters to obtain a sufficient number of antigen-binding molecules for clinical use. Suitable host cells include prokaryotic microorganisms, such as Escherichia coli, or various eukaryotic cells, such as Chinese hamster ovary (CHO) cells, insect cells, and the like. For example, in particular when glycosylation is not required, polypeptides can be generated in bacteria. After expression, the polypeptide can be separated from bacterial cell paste in a soluble fraction and can be further purified. In addition to prokaryotes, eukaryotic microorganisms such as filamentous fungi or yeast are suitable cloning or expression hosts for vectors encoding polypeptides, including fungi and yeast strains whose glycosylation pathways have been "humanized" to produce polypeptides with partial or complete human glycosylation patterns. See Gerngross, Nat Biotech 22, 1409-1414 (2004), and Li et al., Nat Biotech 24, 210-215 (2006).

[0288] Suitable host cells for expressing (glycosylated) polypeptides are also derived from multicellular organisms (invertebrates and vertebrates). Examples of invertebrate cells include plant and insect cells. Numerous baculovirus strains have been identified that can be used in conjunction with insect cells, particularly for transfecting Spodoptera frugiperda cells. Plant cell cultures can also be used as hosts. See, e.g., U.S. Pat. Nos. 5,959,177, 6,040,498, 6,420,548, 7,125,978, and 6,417,429 (describing PLANTIBODIES for producing antibodies in transgenic plants). TMTechniques). Vertebrate cells can also be used as hosts. For example, mammalian cell lines adapted to grow in suspension may be useful. Other examples of useful mammalian host cell lines are monkey kidney CV1 line transformed by SV40 (COS-7), human embryonic kidney cell lines (e.g., 293 or 293T cells as described in Graham et al., J Gen Virol 36, 59 (1977)), baby hamster kidney cells (BHK), mouse Sertoli cells (such as, for example, TM4 cells as described in Mather, Biol Reprod 23, 243-251 (1980)), monkey kidney cells (CV1), African green monkey kidney cells (VERO-76), human cervical carcinoma cells (HELA), canine kidney cells (MDCK), buffalo rat liver cells (BRL 3A), human lung cells (W138), human hepatocytes (Hep G2), mouse mammary tumor cells (MMT 060562), TRI cells (such as, for example, Mather et al., Annals NYAcad Sci 383, 44-68 (1982)), MRC 5 cells, and FS4 cells. Other useful mammalian host cell lines include Chinese hamster ovary (CHO) cells, including dhfr-CHO cells (Urlaub et al., Proc Natl Acad Sci USA 77, 4216 (1980)); and myeloma cell lines such as YO, NS0, P3X63 and Sp2 / 0. For a review of certain mammalian host cell lines suitable for protein production, see, for example, Yazaki and Wu, Methods in Molecular Biology, Vol. 248 (BKCLo, ed., Humana Press, Totowa, NJ), pp. 255-268 (2003). Host cells include cultured cells, such as cultured mammalian cells, yeast cells, insect cells, bacterial cells and plant cells, to name a few, but also transgenic animals, transgenic plants or cells contained in cultured plant or animal tissues. In one embodiment, the host cell is a eukaryotic cell, preferably a mammalian cell, such as a Chinese hamster ovary (CHO) cell, a human embryonic kidney (HEK) cell, or a lymphoid cell (e.g., a Y0, NS0, Sp20 cell). Standard techniques for expressing foreign genes in these systems are known in the art. Cells that can be engineered to express a polypeptide comprising either a heavy or light chain immunoglobulin can also be expressed to express another immunoglobulin chain so that the expressed product is an immunoglobulin with both a heavy and light chain.

[0289] In one aspect, a method for producing an antibody or a polypeptide fragment thereof of the present invention is provided, wherein the method comprises culturing a host cell comprising a polynucleotide encoding the antibody or a polypeptide fragment thereof as provided herein under conditions suitable for expression of the antibody or a polypeptide fragment thereof of the present invention, and recovering the antibody or a polypeptide fragment thereof of the present invention from the host cell (or host cell culture fluid).

[0290] In certain embodiments, the module (e.g., Fab fragment) that can specifically bind to a target cell antigen that forms a part of an antigen binding molecule comprises at least an immunoglobulin variable region that can bind to an antigen. The variable region can form a part of a natural or non-natural antibody and its fragment and derive from it. The method for generating polyclonal antibodies and monoclonal antibodies is well known in the art (see, e.g., Harlow and Lane, "Antibodies, a laboratory manual", Cold Spring Harbor Laboratory, 1988). Non-natural antibodies can be constructed using solid phase peptide synthesis, can be recombinantly generated (e.g., as described in U.S. Patent No. 4,186,567) or can be obtained by, for example, screening a combinatorial library comprising a variable heavy chain and a variable light chain (see, e.g., U.S. Patent No. 5,969,108, granted to McCafferty).

[0291] Immunoglobulins of any animal species can be used in the present invention. Non-limiting immunoglobulins useful in the present invention can be of murine, primate, or human origin. If the fusion protein is intended for human use, a chimeric form of the immunoglobulin can be used, in which the constant region of the immunoglobulin is from a human. Humanized or fully human forms of immunoglobulins can also be prepared according to methods known in the art (see, for example, U.S. Pat. No. 5,565,332 to Winter). Humanization can be achieved by a variety of methods, including but not limited to (a) grafting non-human (e.g., donor antibody) CDRs onto human (e.g., acceptor antibody) frameworks and constant regions with or without retaining key framework residues (e.g., those important for retaining excellent antigen binding affinity or antibody function), (b) grafting only non-human specific determining regions (SDRs or a-CDRs; residues critical for antibody-antigen interactions) onto human frameworks and constant regions, or (c) transplanting entire non-human variable domains, but "covering" them with human-like segments by replacing surface residues.Humanized antibodies and methods for generating them are reviewed, e.g., in Almagro and Fransson, Front Biosci 13, 1619-1633 (2008), and in, e.g., Riechmann et al., Nature 332, 323-329 (1988); Queen et al., Proc Natl Acad Sci USA 86, 10029-10033 (1989); U.S. Pat. Nos. 5,821,337, 7,527,791, 6,982,321, and 7,087,409; Jones et al., Nature 321, 522-525 (1986); Morrison et al., Proc Natl Acad Sci 81, 6851-6855 (1984); Morrison and Oi, Adv Immunol 44, 65-92 (1988); Verhoeyen et al., Science 239, 1534-1536 (1988); Padlan, Molec Immun 31(3), 169-217 (1994); Kashmiri et al., Methods 36, 25-34 (2005) (describing SDR(a-CDR) grafting); Padlan, Mol Immunol 28, 489-498 (1991) (describing "surface remodeling"); Dall'Acqua et al., Methods 36, 43-60 (2005) (describing "FR shuffling"); and Osbourn et al., Methods 36, 61-68 (2005) and Klimka et al., Br J Cancer 83, 252-260 (2000) (describing the "guided selection" approach for FR shuffling). The specific immunoglobulin according to the present invention is a human immunoglobulin. Human antibodies and human variable regions can be generated using a variety of techniques known in the art. Human antibodies are generally described in van Dijk and van de Winkel, Curr Opin Pharmacol 5, 368-74 (2001) and Lonberg, Curr Opin Immunol 20, 450-459 (2008). Human variable regions can form part of and be derived from human monoclonal antibodies generated by the hybridoma method (see, e.g., Monoclonal Antibody Production Techniques and Applications, pp. 51-63 (Marcel Dekker, Inc., New York, 1987)).Human antibodies and human variable regions can also be prepared by administering an immunogen to a transgenic animal that has been modified to produce intact human antibodies or intact antibodies with human variable regions in response to antigenic challenge (see, e.g., Lonberg, Nat Biotech 23, 1117-1125 (2005). Human antibodies and human variable regions can also be produced by isolating Fv clone variable region sequences selected from human-derived phage display libraries (see, e.g., Hoogenboom et al., in Methods in Molecular Biology 178, 1-37 (O'Brien et al., ed., Human Press, Totowa, NJ, 2001); and McCafferty et al., Nature 348, 552-554; Clackson et al., Nature 352, 624-628 (1991)). Phage typically display antibody fragments either as single-chain Fv (scFv) fragments or as Fab fragments.

[0292] In some aspects, according to the method disclosed in, for example, PCT Publication WO 2012 / 020006 (see the embodiment about affinity maturation) or U.S. Patent Application Publication No. 2004 / 0132066, the antibody is engineered to have enhanced binding affinity. The ability of antigen binding molecules of the present invention to bind specific antigenic determinants can be measured via enzyme-linked immunosorbent assay (ELISA) or other techniques familiar to those skilled in the art, such as surface plasmon resonance technology (Liljeblad et al., Glyco J 17, 323-329 (2000)), and traditional binding assays (Heeley, Endocr Res 28, 217-229 (2002)). Competitive assays can be used to identify antigen binding molecules that compete with reference antibodies for binding to specific antigens. In certain embodiments, the epitope (e.g., linear or conformational epitope) bound by such competitive antigen binding molecules is the same as that bound by reference antigen binding molecules. Detailed exemplary methods for mapping epitopes bound by antigen binding molecules are provided in Morris (1996) "Epitope Mapping Protocols", in Methods in Molecular Biology vol.66 (Humana Press, Totowa, NJ). In an exemplary competitive assay, an immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule and a second unlabeled antigen binding molecule (testing its ability to compete with the first antigen binding molecule for binding antigen). The second antigen binding molecule may be present in a hybridoma supernatant. As a control, an immobilized antigen is incubated in a solution comprising a first labeled antigen binding molecule but not comprising a second unlabeled antigen binding molecule. After incubation under conditions that allow the first antibody to bind to the antigen, excess unbound antibodies are removed, and the amount of the marker associated with the immobilized antigen is measured. If the amount of the marker associated with the immobilized antigen in the test sample is substantially reduced relative to the control sample, this indicates that the second antigen binding molecule competes with the first antigen binding molecule for binding antigen. See Harlow and Lane (1988) Antibodies: A Laboratory Manualch. 14 (Cold Spring Harbor Laboratory, Cold Spring Harbor, NY).

[0293] The antibodies of the present invention prepared as described herein can be purified by techniques known in the art, such as high performance liquid chromatography, ion exchange chromatography, gel electrophoresis, affinity chromatography, size exclusion chromatography, etc. The actual conditions for purifying a particular protein will depend in part on factors such as net charge, hydrophobicity, hydrophilicity, and will be apparent to those skilled in the art. For affinity chromatography purification, antibodies, ligands, receptors or antigens in conjunction with antigen binding molecules can be used. For example, for affinity chromatography purification of the fusion protein of the present invention, a matrix with protein A or protein G can be used. Sequential protein A or G affinity chromatography and size exclusion chromatography can be used to separate antigen binding molecules as described in the examples. The purity of antigen binding molecules or their fragments can be determined by any of a variety of well-known analytical methods, including gel electrophoresis, high pressure liquid chromatography, etc. For example, the antigen binding molecules containing 4-1BBL expressed as described in the examples are shown to be complete and correctly assembled, as demonstrated by reducing and non-reducing SDS-PAGE.

[0294] Determination method

[0295] The antigen binding molecules provided herein can be identified, screened, or characterized for their physical / chemical properties and / or biological activities by a variety of assays known in the art.

[0296] 1. Affinity Assay

[0297] The affinity of the bispecific antigen binding molecules provided herein for the corresponding receptors can be determined by surface plasmon resonance (SPR) according to the methods set forth in the examples, using standard instruments such as a BIAcore instrument (GE Healthcare), and receptors or target proteins (such as those obtainable by recombinant expression). The affinity of the bispecific antigen binding molecules for target cell antigens can also be determined by surface plasmon resonance (SPR), using standard instruments such as a BIAcore instrument (GE Healthcare), and receptors or target proteins (such as those obtainable by recombinant expression). For FAP-4-1BBL antigen binding molecules, the methods have been described in more detail in International Patent Application Publication No. WO 2016 / 075278 A1. According to one aspect, at 25°C using K was measured by surface plasmon resonance using a T100 machine (GE Healthcare). D .

[0298] 2. Binding and other assays

[0299] In one aspect, the FAP-4-1BBL antigen binding molecule reported herein is tested for its antigen binding activity as described in more detail in International Patent Application Publication No. WO 2016 / 075278 A1.

[0300] 3. Activity Assay

[0301] In one aspect, assays for identifying the biological activity of FAP-4-1BBL antigen binding molecules are provided.

[0302] In certain embodiments, the antibodies reported herein are tested for such biological activities in in vitro co-culture assays with human immune effector cells.

[0303] Pharmaceutical compositions, formulations and routes of administration

[0304] In yet another aspect, the present invention provides a pharmaceutical composition comprising a 4-1BB agonist provided herein and a HER-2 targeted therapy or a HER-2 targeting agent provided herein, for example, for use in any of the following methods of treatment. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody, a bispecific HER-2 antibody and / or a HER-2 antibody drug conjugate. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and magetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0305] In some aspects, a pharmaceutical composition comprises a 4-1BB agonist provided herein and at least one pharmaceutically acceptable excipient. In other embodiments, a pharmaceutical composition comprises a 4-1BB agonist provided herein and at least one additional therapeutic agent, such as described below. In some embodiments, there is provided a pharmaceutical composition comprising a HER-2 targeting agent and at least one pharmaceutically acceptable excipient.

[0306] The pharmaceutical compositions of the present invention comprise a therapeutically effective amount of one or more antibodies or agents dissolved or dispersed in a pharmaceutically acceptable excipient, carrier, adjuvant or diluent. The phrase "pharmaceutical or pharmaceutically acceptable" refers to molecular entities and compositions that are generally non-toxic to recipients at the dosages and concentrations employed, i.e., do not produce adverse, allergic or other undesirable reactions when properly administered to animals, such as, for example, humans. The preparation of pharmaceutical compositions containing at least one antibody and optionally additional active ingredients will be known to those skilled in the art in light of this disclosure, such as those described in Remington's Pharmaceutical Sciences, 18 th Ed. Mack Printing Company, 1990, exemplified herein by reference. In particular, the composition is a lyophilized formulation or an aqueous solution. As used herein, "pharmaceutically acceptable excipients" include any and all solvents, buffers, dispersion media, coatings, surfactants, antioxidants, preservatives (e.g., antibacterial agents, antifungal agents), isotonic agents, salts, stabilizers and combinations thereof, as would be known to one of ordinary skill in the art.

[0307] Parenteral compositions include those designed for administration by injection, such as subcutaneous, intradermal, intralesional, intravenous, intraarterial, intramuscular, intrathecal or intraperitoneal injection. For injection, the antigen binding molecules of the present invention can be prepared in aqueous solution, preferably in physiologically compatible buffers such as Hanks' solution, Ringer's solution, or saline buffer. The solution may contain a formulation agent, such as a suspension, a stabilizing and / or dispersing agent. Alternatively, the fusion protein may be in powder form for use with a suitable medium, such as sterile pyrogen-free water, before use. As required, a sterile injectable solution is prepared by incorporating the fusion protein of the present invention in a suitable solvent in the required amount with a variety of other components listed below. Sterility can be easily achieved, for example, by filtering through a sterile filter membrane. Generally, dispersions are prepared by incorporating a variety of sterilized active components into a sterile medium containing a basic dispersion medium and / or other components. In the case of sterile powders for the preparation of sterile injectable solutions, suspensions or emulsions, the preferred preparation method is vacuum drying or freeze drying technology, which produces a powder of the active ingredient plus any other desired components from its previously sterile filtered liquid medium. The liquid medium should be properly buffered when necessary and the liquid diluent should first be made isotonic with enough saline or glucose before injection. The composition must be stable under manufacturing and storage conditions, and is antiseptic for microorganisms, such as contamination by bacteria and fungi. It will be appreciated that endotoxin contamination should be kept at a minimum safe level, for example less than 0.5ng / mg protein. Suitable pharmaceutically acceptable excipients include, but are not limited to, buffers such as phosphates, citrates, and other organic acids; antioxidants including ascorbic acid and methionine; preservatives (such as octadecyldimethylbenzyl ammonium chloride; hexamethonium chloride; benzalkonium chloride; benzethonium chloride; phenol, butyl or benzyl alcohol; alkyl parabens such as methyl or propyl paraben; catechol; resorcinol; cyclohexanol; 3-pentanol; and m-cresol); low molecular weight (less than about 10 residues) polypeptides; proteins such as serum albumin. , gelatin, or immunoglobulin; hydrophilic polymers such as polyvinylpyrrolidone; amino acids such as glycine, glutamine, asparagine, histidine, arginine, or lysine; monosaccharides, disaccharides, and other carbohydrates, including glucose, mannose, or dextrin; chelating agents such as EDTA; sugars such as sucrose, mannitol, trehalose or sorbitol; salt-forming counterions such as sodium; metal complexes (e.g., Zn-protein complexes); and / or nonionic surfactants such as polyethylene glycol (PEG). Aqueous injection suspensions may contain compounds that increase the viscosity of the suspension, such as sodium carboxymethylcellulose, sorbitol, dextran, and the like. Optionally, the suspension may also contain suitable stabilizers or agents that increase the solubility of the compound to allow the preparation of highly concentrated solutions. In addition, suspensions of the active compound may be prepared as suitable oily injection suspensions.Suitable lipophilic solvents or vehicles include fatty oils such as sesame oil, or synthetic fatty acid esters, such as ethyl oleate or triglycerides, or liposomes.

[0308] The active ingredient may be embedded in microcapsules prepared, for example, by coacervation techniques or by interfacial polymerization (e.g., hydroxymethylcellulose or gelatin microcapsules and poly(methyl methacrylate) microcapsules, respectively), in colloidal drug delivery systems (e.g., liposomes, albumin microspheres, microemulsions, nanoparticles and nanocapsules) or in macroemulsions. Such techniques are disclosed in Remington's Pharmaceutical Sciences (18th Ed. Mack Printing Company, 1990). Sustained release formulations may be prepared. Suitable examples of sustained release formulations include semipermeable matrices of solid hydrophobic polymers containing the polypeptide, the matrix being in the form of a shaped article, such as a film, or microcapsules. In certain embodiments, prolonged absorption of the injectable composition may be achieved by using an agent that delays absorption in the composition, such as, for example, aluminum monostearate, gelatin, or a combination thereof.

[0309] Exemplary pharmaceutically acceptable excipients herein further include interstitial drug dispersants, such as soluble neutral active hyaluronidase glycoprotein (sHASEGP), for example human soluble PH-20 hyaluronidase glycoprotein, such as rHuPH20 ( Baxter International, Inc.). Certain exemplary sHASEGPs and methods of use (including rHuPH20) are described in U.S. Patent Publication Nos. 2005 / 0260186 and 2006 / 0104968. In one aspect, sHASEGP is combined with one or more additional glycosaminoglycanases such as chondroitinases.

[0310] Exemplary lyophilized antibody formulations are described in US Pat. No. 6,267,958. Aqueous antibody formulations include those described in US Pat. No. 6,171,586 and WO 2006 / 044908, the latter formulations including a histidine-acetate buffer.

[0311] In addition to the compositions described previously, the antigen binding molecules can also be formulated into depot preparations. Such long-acting formulations can be applied by implantation (e.g., subcutaneous or intramuscular) or by intramuscular injection. Thus, for example, the fusion protein can be prepared with suitable polymerization or hydrophobic materials (e.g., as an emulsion in an acceptable oil) or ion exchange resins, or as a slightly soluble derivative, for example, as a slightly soluble salt.

[0312] Pharmaceutical compositions comprising antigen binding molecules of the present invention can be manufactured by conventional mixing, dissolving, emulsifying, encapsulating, embedding or lyophilizing processes. Pharmaceutical compositions can be prepared in a conventional manner using one or more physiologically acceptable carriers, diluents, excipients or adjuvants that promote the processing of proteins into pharmaceutically usable preparations. Appropriate formulations depend on the selected route of administration.

[0313] The antibodies of the present invention can be formulated into compositions in free acid or base, neutral or salt form. Pharmaceutically acceptable salts are salts that substantially retain the biological activity of the free acid or base. These include acid addition salts, such as those formed with free amino groups of proteinaceous compositions or those formed with inorganic acids such as, for example, hydrochloric acid or phosphoric acid, or organic acids such as acetic acid, oxalic acid, tartaric acid or mandelic acid. Salts formed with free carboxyl groups can also be derived from inorganic bases, such as, for example, sodium hydroxide, potassium, ammonium, calcium or iron; or organic bases, such as isopropylamine, trimethylamine, histidine or procaine. Pharmaceutical salts tend to be more soluble in aqueous and other protic solvents than the corresponding free base forms.

[0314] The compositions herein may also contain more than one active ingredient, where required for the particular indication being treated, preferably those with complementary activities that do not adversely affect each other. Such active ingredients are suitably present in combination in amounts that are effective for the intended purpose.

[0315] Formulations to be used for in vivo administration are generally sterile. Sterility can be readily accomplished, for example, by filtration through sterile filtration membranes.

[0316] Administration of 4-1BB agonists and HER-2 targeted therapies

[0317] 4-1BB agonists and HER-2 targeted therapy / HER-2 targeting agents (both referred to as substances herein) can be administered by any suitable means (including parenteral, intrapulmonary, and intranasal, and if desired for local treatment, intralesional administration). However, with regard to therapeutic agents administered by parenteral (particularly intravenous) infusion, the method of the present invention is particularly useful. In some aspects, the HER-2 targeting agent comprises HER-2 antibodies, bispecific HER-2 antibodies and / or HER-2 antibody drug conjugates. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and magetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody-drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0318] Parenteral infusion includes intramuscular, intravenous, intra-arterial, intraperitoneal, or subcutaneous administration. Depending in part on whether the administration is short-lived or long-term, dosing can be performed by any suitable route (e.g., by injection, such as intravenous or subcutaneous injection). Various dosing schedules are contemplated herein, including but not limited to single administration or multiple administrations at multiple time points, push administration, and pulse infusion. In one embodiment, the therapeutic agent is administered parenterally (particularly intravenously). In a specific embodiment, the therapeutic agent is administered by intravenous infusion.

[0319] In some aspects, the 4-1BB agonist and the HER-2 targeting agent are administered together in a single composition. In some embodiments, the 4-1BB agonist and the HER-2 targeting agent are administered separately in two or more different compositions.

[0320] Both 4-1BB agonists and HER-2 targeted therapies / targeting agents will be formulated, dosed, and administered in a manner consistent with excellent medical practice. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the agent delivery site, the method of administration, the schedule of administration, and other factors known to medical practitioners. Both 4-1BB agonists and HER-2 targeted therapies / targeting agents are not required but are optionally formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of therapeutic agents present in the formulation, the type of condition or treatment, and other factors discussed above. These are generally used with the same dosage and route of administration as described herein, or with about 1-99% of the dosage described herein, or with any dosage and any route determined to be suitable empirically / clinically.

[0321] For the prevention or treatment of disease, the appropriate dosage of 4-1BB agonist and HER-2 targeted therapy / targeting agent (when used in combination or with one or more other additional therapeutic agents) will depend on the type of disease to be treated, the type of 4-1BB agent, the severity and course of the disease, whether the two agents are administered for prevention or treatment purposes, previous therapy, the patient's clinical history and response to the therapeutic agent, and the discretion of the attending physician. Each substance is appropriately administered to the patient in one or a series of treatments. Depending on the type and severity of the disease, a substance of about 1 μg / kg to 15 mg / kg (e.g., 0.1 mg / kg-10 mg / kg) can be an initial candidate dose for administration to a subject, such as by one or more separate administrations, or by continuous infusion. Depending on the factors mentioned above, a typical daily dose can range from about 1 μg / kg to 100 mg / kg or more. For repeated administration for several days or longer, depending on the situation, treatment generally continues until the desired disease symptom containment occurs. An exemplary dose of each substance will be in the range of about 0.05 mg / kg to about 10 mg / kg. Thus, one or more doses of about 0.5 mg / kg, 1.0 mg / kg, 2.0 mg / kg, 3.0 mg / kg, 4.0 mg / kg, 5.0 mg / kg, 6.0 mg / kg, 7.0 mg / kg, 8.0 mg / kg, 9.0 mg / kg or 10 mg / kg (or any combination thereof) can be administered to a subject. Such doses can be administered intermittently, for example, weekly, every two weeks, or every three weeks (for example, so that the subject receives about 2 to about 20, or for example, about 6 doses of therapeutic agent). A higher initial loading dose can be administered, followed by one or more lower doses, or a lower initial dose, followed by one or more higher doses. An exemplary dosage regimen comprises administering an initial dose of about 10 mg, followed by a biweekly dose of about 20 mg therapeutic agent. However, other dosage regimens may be useful. The progress of this therapy is easily monitored by conventional techniques and assays.

[0322] In one aspect, the administration of both the 4-1BB agonist and the HER-2 targeted therapy / targeting agent is a single administration. In some embodiments, the 4-1BB agonist and the HER-2 targeted therapy / targeting agent are administered simultaneously. The term "simultaneously" means at the same time or in a shorter period of time, generally less than 1 hour. In some aspects, the administration of the therapeutic agent is twice or more administration. The drug "parallel" administered with one or more other drugs is during the same treatment cycle, with one or more other drugs on the same treatment day, and optionally with one or more other drugs at the same time. For example, for the therapy given every 3 weeks, the drug administered in parallel is each administered on the -1 day of the 3-week cycle. In a specific aspect, weekly, every two weeks, or every three weeks, particularly every two weeks, the substance is administered. In one aspect, the substance is administered in a therapeutically effective amount. In one aspect, the substance is administered at a dose of about 50 μg / kg, about 100 μg / kg, about 200 μg / kg, about 300 μg / kg, about 400 μg / kg, about 500 μg / kg, about 600 μg / kg, about 700 μg / kg, about 800 μg / kg, about 900 μg / kg or about 1000 μg / kg. In one embodiment, the 4-1BB agonist is administered at a dose higher than the dose of the 4-1BB agonist in the corresponding treatment regimen without the Her-2 targeted therapy / targeting agent. In one embodiment, the HER-2 targeted therapy / targeting agent is administered at a dose higher than the dose of the HER-2 targeted therapy / targeting agent in the corresponding treatment regimen without the 4-1BB agonist. In one aspect, the administration of the 4-1BB agonist comprises an initial administration of a first dose of the 4-1BB agonist, and one or more subsequent administrations of a second dose of the 4-1BB agonist, wherein the second dose is higher than the first dose. In one aspect, the administration of the 4-1BB agonist comprises an initial administration of a first dose of the 4-1BB agonist, and one or more subsequent administrations of a second dose of the 4-1BB agonist, wherein the first dose is not lower than the second dose.

[0323] When two therapeutic agents are co-administered sequentially, the agents are administered in two separate administrations separated by a "specific time period". The term specific time period means any time from 1 hour to 15 days. For example, the other agent may be administered within about 1, 2, 3, 4, 5, 6 or 7 days, or 1 to 24 hours of administering one of the agents, and, in one embodiment, the specific time period is 1 to 3 days, or 2 to 8 hours.

[0324] In one aspect, the 4-1BB agonist is administered prior to the administration of the HER-2 targeted therapy / targeting agent. In another aspect, the HER-2 targeted therapy / targeting agent is administered prior to the administration of the 4-1BB agonist.

[0325] In some aspects, the initial pharmaceutically effective amount of trastuzumab emtansine administered per dose will be in the range of about 0.3 to 15 mg / kg / day of patient body weight. Commercial T-DM1 formulations ( Ado-trastuzumab-emtansine) is a sterile, white to off-white, preservative-free lyophilized powder in a disposable vial. Each vial contains 100 mg or 160 mg of ado-trastuzumab-emtansine. After reconstitution, each disposable vial contains ado-trastuzumab-emtansine (20 mg / mL), polysorbate 20 [0.02% (w / v)], sodium succinate (10 mM), and sucrose [6% (w / v)], with a pH of 5.0 and a density of 1.026 g / mL. The resulting solution containing 20 mg / mL ado-trastuzumab-emtansine is administered by intravenous infusion after dilution.

[0326] Commercial formulations of Pertuzumab Pertuzumab 420 mg / 14 mL (30 mg / mL) is contained in a preservative-free solution for IV infusion, and can be administered at a fixed dose of about 420 mg (equivalent to a dose of 6 mg / kg for a 70 kg subject), about 525 mg, about 840 mg, and / or about 1050 mg. Treatment can be started with a higher loading dose (e.g., 840 mg, equivalent to 12 mg / kg body weight). A suitable Pertuzumab formulation for therapeutic use comprises 30 mg / mL Pertuzumab in 20 mM histidine acetate, 120 mM sucrose, 0.02% polysorbate 20, pH 6.0. An alternative Pertuzumab formulation comprises 25 mg / mL Pertuzumab, 10 mM histidine-HCl buffer, 240 mM sucrose, 0.02% polysorbate 20, pH 6.0.

[0327] In another aspect, the 4-1BB agonist is for use with a HER-2 targeted therapy / targeted agent, wherein pretreatment with a type II anti-CD20 antibody, preferably utuzumab, is performed prior to the combination therapy, wherein the time period between the pretreatment and the combination therapy is sufficient to reduce B cells in the individual in response to the type II anti-CD20 antibody, preferably utuzumab.

[0328] The activation of T cells can lead to severe cytokine release syndrome (CRS). In a Phase 1 study conducted by TeGenero (Suntharalingam et al., N Engl J Med (2006) 355, 1018-1028), all 6 healthy volunteers rapidly experienced near-lethal, severe cytokine release syndrome (CRS) after infusion of inappropriate doses of T cell stimulating super-agonistic anti-CD28 monoclonal antibodies. Cytokine release related to administering T cell activating therapeutic agents to subjects, such as 4-1BB agonists described herein, can be significantly reduced by pre-treating the subject with type II anti-CD20 antibodies, such as obinutuzumab. The use of pre-treatment (Gpt) should help to rapidly deplete B cells in both peripheral blood and secondary lymphoid organs, so that the risk of highly relevant adverse events (AEs) (e.g., CRS) from strong systemic T cell activation caused by T cell activating therapeutics is reduced, while supporting T cell activating therapeutics at exposure levels high enough to mediate tumor cell elimination from the beginning of dosing. To date, the safety profile of Obinutuzumab (including cytokine release) has been evaluated and managed in hundreds of patients in ongoing clinical trials of Obinutuzumab. Finally, in addition to supporting the safety profile of T cell activating antibodies, Gpt should also help prevent the formation of anti-drug antibodies (ADA) against these unique molecules.

[0329] In the present invention, the combination of 4-1BB agonist and HER-2 targeted therapy / targeting agent can be used in combination with other agents in therapy. For example, at least one additional therapeutic agent can be co-administered. In some aspects, the additional therapeutic agent is an immunotherapeutic agent. In some embodiments, the additional therapeutic agent is a chemotherapeutic agent. Suitable chemotherapeutic agents include one or more: anthracycline antibiotic drugs, such as doxorubicin and epirubicin Taxane drugs, such as paclitaxel and docetaxel Fluorouracil (5FU); cyclophosphamide; methotrexate; cisplatin; and capecitabine. Other additional therapeutic agents include the kinase inhibitors lapatinib (Tykerb) and neratinib (Nerlynx).

[0330] Such combination therapies noted above encompass combined administration (where two or more therapeutic agents are included in the same formulation or in separate formulations), and separate administration (in which case administration of the therapeutic agent can occur before, simultaneously with, and / or after administration of one or more additional therapeutic agents). In one embodiment, administration of the therapeutic agent and administration of the additional therapeutic agent occur within about 1 month, or within about 1, 2, or 3 weeks, or within about 1, 2, 3, 4, 5, or 6 days of each other.

[0331] Methods of treatment and compositions

[0332] In one aspect, provided is a method for treating cancer or delaying cancer progression in an individual, the method comprising administering an effective amount of a 4-1BB agonist described herein and an effective amount of a HER-2 targeting agent described herein to a subject. In various aspects, the HER-2 targeting agent comprises a HER-2 antibody, a bispecific HER-2 antibody and / or a HER-2 antibody drug conjugate. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and magetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody-drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0333] In one such aspect, the method further comprises administering to the individual an effective amount of at least one additional therapeutic agent. Suitable additional agents include one or more: anthracycline antibiotics, such as doxorubicin and epirubicin. Taxane drugs, such as paclitaxel and docetaxel Fluorouracil (5FU); cyclophosphamide; methotrexate; cisplatin; and capecitabine. Other suitable additional therapeutic agents include kinase inhibitors lapatinib (Tykerb) and neratinib (Nerlynx). In some other embodiments, a method for tumor shrinkage is provided herein, the method comprising administering an effective amount of a 4-1BB agonist and a HER-2 targeting agent to a subject, as described herein. According to any of the above aspects, an "individual" or "subject" is preferably a person.

[0334] In one aspect, the present invention provides a 4-1BB agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent. In another aspect, the present invention provides a 4-1BB agonist and a HER-2 targeting agent for use in a method for treating cancer or delaying cancer progression. In some embodiments, the 4-1BB agonist and / or the HER-2 targeting agent are combined with another therapeutic agent.

[0335] In some other aspects, a composition for use in cancer immunotherapy is provided, comprising a 4-1BB agonist and a HER-2 targeting agent. In certain embodiments, a composition comprising a 4-1BB agonist and a HER-2 targeting agent is provided for use in a method of cancer immunotherapy.

[0336] In yet another aspect, provided herein is the use of a composition comprising a 4-1BB agonist and a HER-2 targeting agent in the manufacture or preparation of a drug. In some embodiments, the drug is used to treat cancer. In some embodiments, the drug is used to treat solid tumors. In some embodiments, the drug is used in a method for shrinking a tumor, the method comprising administering an effective amount of a drug to an individual with a solid tumor. In one such embodiment, the method further comprises administering an effective amount of at least one additional therapeutic agent to an individual. In some embodiments, the drug is used to treat solid tumors.

[0337] In certain aspects, the individual has a HER-2 positive cancer. In some embodiments, the cancer may comprise cells that overexpress HER-2. In some embodiments, the cancer comprises a solid tumor. In some embodiments, the solid tumor is an advanced and / or metastatic solid tumor. In some aspects, the HER-2 positive cancer is breast cancer, ovarian cancer, gastric cancer, gastric cancer, esophageal cancer, lung cancer, such as adenocarcinoma of the lung or non-small cell lung cancer (NSCLC), uterine cancer, such as uterine serous endometrial cancer, salivary duct cancer, bladder cancer, endometrial cancer, pancreatic cancer, colon cancer, prostate cancer, and / or head and neck cancer. In some aspects, the breast cancer is a breast cancer tumor or a breast adenocarcinoma. In some aspects, the breast cancer tumor is an invasive ductal carcinoma. In some aspects, the lung cancer is a lung adenocarcinoma. In some embodiments, the colon cancer is a colorectal adenocarcinoma. According to any of the above embodiments, the "individual" can be a human.

[0338] In some aspects, the cancer is HER-2 positive breast cancer, particularly metastatic breast cancer (IV stage breast cancer). In some aspects, the cancer is II or III stage HER-2 positive breast cancer. In some aspects, the cancer is HER-2 positive early breast cancer. In some aspects, the cancer is HER-2 positive gastric cancer.

[0339] Treatment can be intended to prevent the occurrence or progression of cancer. In this way, the 4-1BB agonists and HER-2 targeting agents described herein can be used to preventively treat subjects for the occurrence of disease states. This can occur before the onset of symptoms of the disease state, and / or can be given to subjects who are considered to be at greater risk of cancer occurrence or progression.

[0340] In some embodiments, the 4-1BB agonist acts synergistically with the HER-2 targeting agent.

[0341] The combination therapy recorded above covers combined administration (wherein two or more therapeutic agents are included in the same formulation or separate formulations), and separate administration, in which case, the administration of the antibody reported herein can occur before, simultaneously, and / or after the administration of one or more additional therapeutic agents. In one embodiment, the administration of 4-1BB agonists and HER-2 targeting agents and the administration of optional additional therapeutic agents occur within about 1 month, or within about 1, 2 or 3 weeks, or within about 1, 2, 3, 4, 5, or 6 days.

[0342] Both 4-1BB agonists and HER-2 targeting agents described herein (and any other therapeutic agent) can be administered by any suitable means (including parenteral, intrapulmonary, and intranasal, and if desired for local treatment, intralesion administration). Parenteral infusion includes intramuscular, intravenous, intraarterial, intraperitoneal, or subcutaneous administration. Partly depending on whether the administration is short-lived or long-term, dosing can be performed by any suitable path (e.g., by injection, such as intravenous or subcutaneous injection). Various dosing schedules are contemplated herein, including but not limited to single administration or multiple administrations at multiple time points, push administration, and pulse infusion.

[0343] The 4-1BB agonists and HER-2 targeting agents described herein are both formulated, dosed, and administered in a manner consistent with excellent medical practice. Factors considered in this context include the specific condition being treated, the specific mammal being treated, the clinical condition of the individual patient, the cause of the condition, the agent delivery site, the method of administration, the administration schedule, and other factors known to medical practitioners. Antibodies are not required but are optionally formulated with one or more agents currently used to prevent or treat the condition in question. The effective amount of such other agents depends on the amount of antibodies present in the formulation, the type of condition or treatment, and other factors discussed above. These are generally used with the same dosage and route of administration as described herein, or with about 1-99% of the dosage described herein, or with any dosage and any route determined to be suitable empirically / clinically.

[0344] Products (Kits)

[0345] In another aspect of the present invention, a kit is provided, which contains materials useful for treating, preventing and / or diagnosing the above-described illness. The kit comprises at least one container and a label or package insert on or in combination with the container. Suitable containers include, for example, bottles, vials, syringes, IV solution bags, etc. The container can be formed from a variety of materials such as glass or plastic. The container is equipped with a composition that effectively treats, prevents and / or diagnoses the condition by itself or in combination with another composition and may have a sterile access port (for example, the container may be a vial or intravenous solution bag with a stopper pierceable by a hypodermic injection needle). At least two active agents in the kit are 4-1BB agonists and HER-2 targeting agents of the present invention. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody, a bispecific HER-2 antibody and / or a HER-2 antibody drug conjugate. In some aspects, the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent is selected from the group consisting of trastuzumab, pertuzumab, and trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a combination of trastuzumab, pertuzumab, and / or trastuzumab emtansine. In some aspects, the HER-2 targeting agent comprises a HER-2 antibody selected from the group consisting of trastuzumab, pertuzumab and magetuximab. In one aspect, the HER-2 targeting agent is trastuzumab or pertuzumab. More particularly, the HER-2 targeting agent is trastuzumab. In some aspects, the HER-2 targeting agent is a glycoengineered HER-2 antibody, such as TrasGex. In some aspects, the HER-2 targeting agent is a bispecific HER-2 antibody, such as Herceptarg. In some aspects, the HER-2 targeting agent is a HER-2 antibody drug conjugate, particularly trastuzumab emtansine (ado-trastuzumab emtansine).

[0346] In one specific aspect, provided is a kit for treating cancer or delaying cancer progression in a subject, comprising a package comprising (A) a first composition comprising a 4-1BB agonist as an active ingredient and a pharmaceutically acceptable carrier; (B) a second composition comprising a HER-2 targeting agent as an active ingredient and a pharmaceutically acceptable carrier, and (C) instructions for use of the composition in combination therapy.

[0347] The label or package insert indicates how the composition is used to treat the selected condition and provides instructions for using the composition in a combination therapy. In addition, the kit may include (a) a first container containing a composition, wherein the composition comprises a 4-1BB agonist of the present invention; and (b) a second container containing a composition, wherein the composition comprises a HER-2 targeting agent of the present invention. In addition, the kit may include one or more other containers containing other active components that can be used in combination. The article in this embodiment of the present invention may further include a package insert indicating that the composition can be used to treat a specific condition.

[0348] Alternatively or additionally, the kit may further comprise a second (or third) container comprising a pharmaceutically acceptable buffer, such as bacteriostatic water for injection (BWFI), phosphate-buffered saline, Ringer's solution and dextrose solution. It may further include other materials desirable from a commercial and user standpoint, including other buffers, diluents, filters, needles, and syringes.

[0349] Table C (sequence)

[0350]

[0351]

[0352]

[0353]

[0354]

[0355]

[0356]

[0357]

[0358]

[0359] General information about the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991). The amino acids of the antibody chains are numbered and referred to according to the numbering system according to Kabat as defined above (Kabat, EA et al., Sequences of Proteins of Immunological Interest, 5th ed., Public Health Service, National Institutes of Health, Bethesda, MD (1991)).

[0360] Aspects of the Invention

[0361] In the following, some aspects of the invention are listed.

[0362] 1. A 4-1BB agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent.

[0363] 2. A 4-1BB agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen.

[0364] 3. The 4-1BB agonist for use in the method of aspect 1, wherein the 4-1BB agonist and the HER-2 targeting agent are administered together in a single composition or separately in two or more different compositions.

[0365] 4. The 4-1BB agonist for use in the method of aspect 1 or 2, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.

[0366] 5. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

[0367] 6. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.

[0368] 7. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to fibroblast activation protein (FAP).

[0369] 8. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises

[0370] (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or

[0371] (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V HFAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0372] 9. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 21. H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 24 L FAP).

[0373] 10. The 4-1BB agonist for use in the method according to the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.

[0374] 11. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to Fc receptors and / or effector function.

[0375] 12. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0376] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0377] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0378] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0379] 13. The 4-1BB agonist for use in the method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0380] (a) at least one Fab domain capable of specifically binding to CD19, and

[0381] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0382] wherein the antigen binding molecule is characterized by

[0383] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0384] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0385] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0386] 14. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0387] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain specifically binding to FAP comprising a heavy chain variable region (V HFAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 H FAP) and a light chain variable region (V L ... L FAP), and

[0388] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0389] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0390] 15. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:

[0391] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:41, a first light chain comprising the amino acid sequence of SEQ ID NO:42, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and

[0392] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, a first light chain comprising the amino acid sequence of SEQ ID NO:46, a second heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a second light chain comprising the amino acid sequence of SEQ ID NO:48.

[0393] 16. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0394] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0395] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0396] 17. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0397] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0398] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0399] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0400] 18. The 4-1BB agonist for use in the method according to the preceding aspects, wherein the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0401] 19. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA.

[0402] 20. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises (a) a heavy chain variable region (V H CEA and light chain variable region (V L CEA), the heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, the light chain variable region (V L CEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0403] 21. The 4-1BB agonist for use in the method of the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises a heavy chain variable region (V L ... H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0404] 22. The 4-1BB agonist for use in the method according to the aforementioned aspect, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.

[0405] 23. The 4-1BB agonist for use in the method of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0406] 24. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0407] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0408] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0409] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0410] 25. The 4-1BB agonist for use in the method of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0411] (a) at least one Fab domain capable of specifically binding to CEA, and

[0412] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0413] wherein the antigen binding molecule is characterized by

[0414] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0415] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0416] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0417] 26. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0418] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0419] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0420] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0421] 27. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO: 41, a first light chain comprising an amino acid sequence of SEQ ID NO: 42, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 82, and a second light chain comprising an amino acid sequence of SEQ ID NO: 83.

[0422] 28. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0423] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0424] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0425] 29. The 4-1BB agonist for use in the method of the aforementioned aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising the following:

[0426] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0427] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0428] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0429] 30. The 4-1BB agonist for use in the method of the preceding aspects, wherein the 4-1BB agonist is an anti-CEA / anti-4-1BB bispecific antibody.

[0430] 31. The 4-1BB agonist for use in a method according to any one of the preceding aspects, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the combination is administered at intervals of about one to three weeks.

[0431] 32. A pharmaceutical product comprising (A) a first composition comprising a 4-1BB agonist as an active ingredient and a pharmaceutically acceptable carrier; and (B) a second composition comprising a HER-2 targeting agent as an active ingredient and a pharmaceutically acceptable carrier, for use in combination, sequentially or simultaneously, in the treatment of a disease, particularly cancer.

[0432] 33. A pharmaceutical composition comprising a 4-1BB agonist and a HER-2 targeting agent.

[0433] 34. The pharmaceutical composition of aspect 32, for use in treating solid tumors.

[0434] 35. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.

[0435] 36. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

[0436] 37. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.

[0437] 38. The pharmaceutical composition according to any one of the preceding aspects, wherein the tumor-associated antigen is FAP.

[0438] 39. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises

[0439] (a) Heavy chain variable region (V H FAP and light chain variable region (V LFAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or

[0440] (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0441] 40. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 21. H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).

[0442] 41. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.

[0443] 42. The pharmaceutical composition according to any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain.

[0444] 43. The pharmaceutical composition of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0445] 44. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.

[0446] 45. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0447] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0448] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0449] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0450] 46. ​​The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0451] (a) at least one Fab domain capable of specifically binding to FAP, and

[0452] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0453] wherein the antigen binding molecule is characterized by

[0454] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0455] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0456] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0457] 47. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0458] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 H FAP) and a light chain variable region (V L ... L FAP), and

[0459] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0460] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0461] 48. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:

[0462] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:41, a first light chain comprising the amino acid sequence of SEQ ID NO:42, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and

[0463] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, a first light chain comprising the amino acid sequence of SEQ ID NO:46, a second heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a second light chain comprising the amino acid sequence of SEQ ID NO:48.

[0464] 49. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0465] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0466] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0467] 50. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0468] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0469] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0470] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0471] 51. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0472] 52. The pharmaceutical composition of any one of the preceding aspects, wherein the tumor-associated antigen is CEA.

[0473] 53. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA, wherein the antigen binding domain capable of specifically binding to CEA comprises a heavy chain variable region (V H CEA and light chain variable region (V L CEA), the heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, the light chain variable region (V L CEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0474] 54. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to CEA, wherein the antigen binding domain capable of specific binding to CEA comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 39. H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0475] 55. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.

[0476] 56. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain.

[0477] 57. The pharmaceutical composition of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0478] 58. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG1 Fc domain comprising amino acid substitutions L234A, L235A and P329G.

[0479] 59. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0480] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0481] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0482] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0483] 60. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0484] (a) at least one Fab domain capable of specifically binding to CEA, and

[0485] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0486] wherein the antigen binding molecule is characterized by

[0487] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0488] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0489] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0490] 61. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0491] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0492] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0493] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0494] 62. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO: 41, a first light chain comprising an amino acid sequence of SEQ ID NO: 42, a second heavy chain comprising an amino acid sequence of SEQ ID NO: 82, and a second light chain comprising an amino acid sequence of SEQ ID NO: 83.

[0495] 63. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0496] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0497] (b) A polypeptide comprising 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker.

[0498] 64. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0499] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0500] (b) a polypeptide comprising three 4-1BBL ectodomains or fragments thereof linked to each other via a peptide linker, and

[0501] (c) an Fc domain consisting of a first and a second subunit capable of stably associating, wherein the polypeptide comprising three 4-1BBL outer domains or fragments thereof connected to each other by a peptide linker is fused to the N- or C-terminal amino acid of one of the two subunits of the Fc domain, optionally via a peptide linker.

[0502] 65. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is an anti-CEA / anti-4-1BB bispecific antibody.

[0503] 66. The 4-1BB agonist or pharmaceutical composition for use according to any of the preceding aspects, wherein the HER-2 targeting agent is one or more of trastuzumab, pertuzumab, and / or trastuzumab emtansine.

[0504] 67. The 4-1BB agonist or pharmaceutical composition for use according to any one of the preceding aspects, wherein the HER-2 targeting agent is trastuzumab.

[0505] 68. The pharmaceutical composition of any one of the preceding aspects, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the combination is administered at intervals of about one to three weeks.

[0506] 69. The pharmaceutical composition according to any of the preceding aspects, for use in treating a proliferative disease, particularly cancer, or in delaying the progression of a proliferative disease, particularly cancer.

[0507] 70. The pharmaceutical composition of any of the preceding aspects, for use in the treatment of breast cancer, ovarian cancer, gastric cancer, gastric cancer, esophageal cancer, lung cancer, uterine cancer, salivary duct cancer, bladder cancer, endometrial cancer, pancreatic cancer, colon cancer, prostate cancer, and / or head and neck cancer.

[0508] 71. A kit for treating cancer or delaying cancer progression in a subject, comprising a package comprising (A) a first composition comprising a 4-1BB agonist as an active ingredient and a pharmaceutically acceptable carrier; (B) a second composition comprising a HER-2 targeting agent as an active ingredient and a pharmaceutically acceptable carrier, and (C) instructions for use of the composition in combination therapy.

[0509] 72. Use of a combination of a 4-1BB agonist and a HER-2 targeting agent in the manufacture of a medicament for treating a proliferative disease, particularly cancer, or delaying the progression of a proliferative disease, particularly cancer.

[0510] 73. Use of a combination of a 4-1BB agonist and a HER-2 targeting agent in the manufacture of a medicament for the treatment of solid tumors.

[0511] 74. A method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist and an effective amount of a HER-2 targeting agent.

[0512] 75. A method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject an effective amount of a 4-1BB agonist and an effective amount of a HER-2 targeting agent, wherein the 4-1BB agonist is an antigen binding molecule.

[0513] 76. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain.

[0514] 77. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising a modified Fc domain that reduces Fcγ receptor binding and / or effector function.

[0515] 78. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof.

[0516] 79. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and an antigen binding domain capable of specifically binding to a tumor associated antigen.

[0517] 80. The method of any one of the preceding aspects, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

[0518] 81. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one module capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises

[0519] (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (VH FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or

[0520] (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0521] 82. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL external domains or fragments thereof and at least one antigen binding domain capable of specifically binding to FAP, wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H ) comprising the amino acid sequence of SEQ ID NO: 21. H FAP) and a light chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 22 L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).

[0522] 83. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.

[0523] 84. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, in particular an IgG1 Fc domain or an IgG4 Fc domain.

[0524] 85. The method of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0525] 86. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0526] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0527] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0528] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0529] 87. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0530] (a) at least one Fab domain capable of specifically binding to FAP, and

[0531] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0532] wherein the antigen binding molecule is characterized by

[0533] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0534] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0535] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0536] 88. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0537] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 H FAP) and a light chain variable region (V L ... L FAP), and

[0538] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0539] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0540] 89. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule selected from the group consisting of:

[0541] a) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:41, a first light chain comprising the amino acid sequence of SEQ ID NO:42, a second heavy chain comprising the amino acid sequence of SEQ ID NO:43, and a second light chain comprising the amino acid sequence of SEQ ID NO:44; and

[0542] b) a molecule comprising a first heavy chain comprising the amino acid sequence of SEQ ID NO:45, a first light chain comprising the amino acid sequence of SEQ ID NO:46, a second heavy chain comprising the amino acid sequence of SEQ ID NO:47, and a second light chain comprising the amino acid sequence of SEQ ID NO:48.

[0543] 90. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0544] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0545] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0546] 91. The method of any of the preceding aspects, wherein the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0547] 92. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one module capable of specific binding to CEA, wherein the antigen binding domain capable of specific binding to CEA comprises a heavy chain variable region (V H CEA and light chain variable region (V L CEA), the heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, the light chain variable region (V L CEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0548] 93. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL outer domains or fragments thereof and at least one antigen binding domain capable of specific binding to CEA, wherein the antigen binding domain capable of specific binding to CEA comprises a heavy chain variable region (V H ) comprising an amino acid sequence of SEQ ID NO: 39. H CEA) and a light chain variable region (V L CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0549] 94. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule further comprising an Fc domain consisting of a first and a second subunit capable of stably associating.

[0550] 95. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, particularly an IgG1 Fc domain or an IgG4 Fc domain.

[0551] 96. The method of any of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0552] 97. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0553] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0554] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0555] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0556] 98. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0557] (a) at least one Fab domain capable of specifically binding to CEA, and

[0558] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0559] wherein the antigen binding molecule is characterized by

[0560] (i) respectively, the first polypeptide contains a CH1 or CL domain and the second polypeptide contains a CL or CH1 domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof linked to each other and to the CH1 or CL domain via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extradomain or fragment thereof linked to the CL or CH1 domain of said polypeptide via a peptide linker, or

[0561] (ii) respectively, the first polypeptide contains a CH3 domain and the second polypeptide contains a CH3 domain, and wherein the first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other and to the C-terminus of the CH3 domain via a peptide linker and wherein the second polypeptide comprises one 4-1BBL extradomain or fragment thereof connected to the C-terminus of the CH3 domain of said polypeptide via a peptide linker, or

[0562] (iii) respectively, the first polypeptide contains a VH-CL or VL-CH1 domain and the second polypeptide contains a VL-CH1 domain or a VH-CL domain, wherein the second polypeptide is linked to the first polypeptide via a disulfide bond between the CH1 and CL domains, and wherein the first polypeptide comprises two 4-1BBL extracellular domains or fragments thereof linked to each other and to VH or VL via a peptide linker and wherein the second polypeptide comprises a 4-1BBL extracellular domain or fragment thereof linked to the VL or VH of said polypeptide via a peptide linker.

[0563] 99. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0564] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0565] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0566] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0567] 100. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO:41, a first light chain comprising an amino acid sequence of SEQ ID NO:42, a second heavy chain comprising an amino acid sequence of SEQ ID NO:82, and a second light chain comprising an amino acid sequence of SEQ ID NO:83.

[0568] 101. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0569] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0570] (b) A polypeptide comprising three 4-1BBL ectodomains or fragments thereof connected to each other via a peptide linker.

[0571] 102. The method of any one of the preceding aspects, wherein the 4-1BB agonist is an anti-CEA / anti-4-1BB bispecific antibody.

[0572] 103. The method of any of the preceding aspects, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the combination is administered at intervals of about one to three weeks.

[0573] 104. The method of any of the preceding aspects, wherein the 4-1BB agonist and the HER-2 targeting agent are administered together in a single composition or separately in two or more different compositions.

[0574] 105. The method of any one of the preceding aspects, wherein the 4-1BB agonist and the HER-2 targeting agent are administered intravenously or subcutaneously.

[0575] 106. The method of any of the preceding aspects, wherein the 4-1BB agonist is administered concurrently with, before, or after the HER-2 targeting agent.

[0576] 107. The method of any one of the preceding aspects, wherein the 4-1BB agonist and the HER-2 targeting agent are administered simultaneously.

[0577] 108. The 4-1BB agonist of any preceding aspect for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein the 4-1BB agonist acts synergistically with the HER-2 targeting agent.

[0578] 109. A 4-1BB agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB agonist is used in combination with a HER-2 targeting agent and wherein pretreatment with a type II anti-CD20 antibody is performed prior to the combined treatment, wherein the time period between the pretreatment and the combined treatment is sufficient to reduce B cells in the individual in response to the type II anti-CD20 antibody.

[0579] 110. The 4-1BB agonist for use in the method of aspect 109, wherein the type II anti-CD20 antibody is obinutuzumab.

[0580] 111. A method for treating cancer or delaying cancer progression in a subject, comprising administering to the subject a combination of an effective amount of a 4-1BB agonist and an effective amount of a HER-2 targeting agent, wherein pretreatment with a type II anti-CD20 antibody is performed prior to treatment with the combination, wherein the time period between the pretreatment and the combination treatment is sufficient to reduce B cells in the individual in response to the type II anti-CD20 antibody.

[0581] 112. The method of aspect 111, wherein the type II anti-CD20 antibody is obinutuzumab.

[0582] 113. A combination comprising a 4-1BB (CD137) agonist and a HER-2 targeting agent, wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain capable of specifically binding to a tumor-associated antigen.

[0583] 114. The combination of aspect 113, wherein the HER-2 targeting agent comprises a HER-2 antibody, a HER-2 bispecific antibody and / or a HER-2 antibody drug conjugate.

[0584] 115. The combination of aspect 113 or 114, wherein the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine.

[0585] 116. The combination of any one of the preceding aspects, wherein the 4-1BB agonist comprises three 4-1BBL ectodomains or fragments thereof.

[0586] 117. A combination of any one of the preceding aspects, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO: 5.

[0587] 118. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen selected from the group consisting of fibroblast activation protein (FAP) and CEA.

[0588] 119. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, particularly an IgG1 Fc domain or an IgG4 Fc domain.

[0589] 120. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

[0590] 121. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to fibroblast activation protein (FAP).

[0591] 122. The combination of any one of the preceding aspects, wherein the antigen binding domain capable of specifically binding to a tumor-associated antigen is an antigen binding domain capable of specifically binding to FAP comprising:

[0592] (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V HFAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or

[0593] (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.

[0594] 123. The combination of any one of the preceding aspects, wherein the antigen binding domain capable of specifically binding to a tumor-associated antigen is an antigen binding domain capable of specifically binding to FAP, the antigen binding domain capable of specifically binding to FAP comprising a heavy chain variable region (V L ... H FAP) and a light chain variable region (V L ... L FAP) or wherein the antigen binding domain capable of specifically binding to FAP comprises a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP).

[0595] 124. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0596] (a) at least one antigen binding domain capable of specifically binding to FAP,

[0597] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0598] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0599] 125. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0600] (a) at least one Fab domain capable of specifically binding to FAP, the Fab domain capable of specifically binding to FAP comprising a heavy chain variable region (V H FAP) and a light chain variable region (V L ... L FAP) or a heavy chain variable region (V FAP) comprising the amino acid sequence of SEQ ID NO: 23 H FAP) and a light chain variable region (V L ... L FAP), and

[0601] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0602] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0603] 126. A combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising a first heavy chain comprising an amino acid sequence of SEQ ID NO:41, a first light chain comprising an amino acid sequence of SEQ ID NO:42, a second heavy chain comprising an amino acid sequence of SEQ ID NO:43, and a second light chain comprising an amino acid sequence of SEQ ID NO:44.

[0604] 127. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an anti-FAP / anti-4-1BB bispecific antibody.

[0605] 128. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to CEA.

[0606] 129. A combination of any one of the preceding aspects, wherein the antigen binding domain capable of specifically binding to a tumor-associated antigen is an antigen binding domain capable of specifically binding to CEA, the antigen binding domain capable of specifically binding to CEA comprising (a) a heavy chain variable region (V H CEA and light chain variable region (V L CEA), the heavy chain variable region (V H CEA) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 33, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 34, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 35, the light chain variable region (V L CEA) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO:36, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO:37, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO:38.

[0607] 130. A combination of any one of the preceding aspects, wherein the antigen binding domain capable of specifically binding to a tumor-associated antigen is an antigen binding domain capable of specifically binding to CEA, the antigen binding domain capable of specifically binding to CEA comprising a heavy chain variable region (V L ... H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA).

[0608] 131. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0609] (a) at least one antigen binding domain capable of specifically binding to CEA,

[0610] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0611] The first polypeptide comprises two 4-1BBL extradomains or fragments thereof connected to each other via a peptide linker and the second polypeptide comprises one 4-1BBL extradomain or fragment thereof.

[0612] 132. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an antigen binding molecule comprising:

[0613] (a) at least one Fab domain capable of specifically binding to CEA, the Fab domain capable of specifically binding to CEA comprising a heavy chain variable region (V H CEA) and a light chain variable region (V CEA) comprising the amino acid sequence of SEQ ID NO: 40 L CEA), and

[0614] (b) a first and a second polypeptide linked to each other via a disulfide bond,

[0615] The antigen binding molecule is characterized in that the first polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:25, SEQ ID NO:26, SEQ ID NO:27, SEQ ID NO:28, SEQ ID NO:29, SEQ ID NO:30, SEQ ID NO:31 and SEQ ID NO:32 and the second polypeptide comprises an amino acid sequence selected from the group consisting of SEQ ID NO:1, SEQ ID NO:2, SEQ ID NO:3, SEQ ID NO:4, SEQ ID NO:5, SEQ ID NO:6, SEQ ID NO:7 and SEQ ID NO:8.

[0616] 133. The combination of any one of the preceding aspects, wherein the 4-1BB agonist is an anti-CEA / anti-4-1BB bispecific antibody.

[0617] 134. A combination according to any of the preceding aspects for use as a medicine.

[0618] 135. The combination of any one of the preceding aspects, wherein the 4-1BB agonist and the HER-2 targeting agent are administered together in a single composition or separately in two or more different compositions.

[0619] 136. The combination of any one of the preceding aspects, wherein the 4-1BB agonist and the HER-2 targeting agent are for simultaneous administration or sequential administration.

[0620] 137. A combination according to any of the preceding aspects, for use in the treatment of HER-2 positive cancer.

[0621] Example

[0622] The following are examples of methods and compositions of the present invention. It is understood that various other embodiments may be practiced, given the general description provided above.

[0623] Recombinant DNA technology

[0624] Standard methods are used for manipulation of DNA, such as described in Sambrook et al., Molecular cloning: A laboratory manual; Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York, 1989. Molecular biology reagents are used according to the manufacturer's instructions. General information on the nucleotide sequences of human immunoglobulin light and heavy chains is given in Kabat, EA et al., (1991) Sequences of Proteins of Immunological Interest, Fifth Ed., NIH Publication No 91-3242.

[0625] DNA Sequencing

[0626] The DNA sequence was determined by double-strand sequencing.

[0627] Gene synthesis

[0628] The desired gene segments are either generated by PCR using suitable templates or synthesized by automated gene synthesis from synthetic oligonucleotides and PCR products by Geneart AG (Regensburg, Germany). In the case where the exact gene sequence is not available, oligonucleotide primers are designed based on the sequence from the nearest homolog, and the gene is isolated from RNA derived from suitable tissues by RT-PCR. The gene segments flanked by single restriction endonuclease cleavage sites are cloned into standard cloning / sequencing vectors. Plasmid DNA is purified from transformed bacteria and concentration is determined by UV spectroscopy. The DNA sequence of the subcloned gene fragments is confirmed by DNA sequencing. The gene segments are designed to have suitable restriction sites to allow subcloning into corresponding expression vectors. All constructs are designed to have a 5' end DNA sequence encoding a leader peptide that targets protein secretion in eukaryotic cells.

[0629] Cell culture technology

[0630] Standard cell culture techniques are used as described in Current Protocols in Cell Biology (2000), Bonifacino, JS, Dasso, M., Harford, JB, Lippincott-Schwartz, J. and Yamada, KM (eds.), John Wiley & Sons, Inc.

[0631] Protein purification

[0632] Proteins were purified from filtered cell culture supernatants with reference to standard protocols. In brief, antibodies were applied to protein A Sepharose columns (GE Healthcare) and washed with PBS. Elution of the antibodies was achieved at pH 2.8, followed by immediate neutralization of the sample. Aggregated proteins were separated from monomeric antibodies by size exclusion chromatography (Superdex200, GE Healthcare) in PBS or in 20 mM histidine, 150 mM NaCl pH 6.0. Monomeric antibody fractions were combined, concentrated (when needed) using, for example, MILLIPORE Amicon Ultra (30 MWCO) centrifugal concentrators, frozen and stored at -20 ° C or -80 ° C. Partial samples were provided for subsequent protein analysis and analytical characterization, for example, by SDS-PAGE, size exclusion chromatography (SEC) or mass spectrometry.

[0633] SDS-PAGE

[0634] Use according to the manufacturer's instructions Precast gel system (Invitrogen). In particular, 10% or 4-12% Bis-TRIS precast gel (pH 6.4) and MES (reducing gel, with Antioxidant running buffer additive) or MOPS (non-reducing gel) running buffer.

[0635] Analytical size exclusion chromatography

[0636] Size exclusion chromatography (SEC) is implemented by HPLC chromatography, for measuring the aggregation and oligomeric state of antibody. In brief, the antibody purified by protein A is applied to 300mM NaCl, 50mM KH2PO4 / K2HPO4, Superdex 200 post (GE Healthcare) in 2x PBS on Tosoh TSKgel G3000SW post or Dionex HPLC system in pH 7.5. The protein of elution is quantified by UV absorbance and peak area integration. BioRad gel filtration standard 151-1901 serves as standard.

[0637] Mass spectrometry

[0638] This section describes the characterization of multispecific antibodies with VH / VL exchange (VH / VL CrossMab) with emphasis on their correct assembly. The expected primary structure was analyzed by electrospray ionization mass spectrometry (ESI-MS) of deglycosylated intact CrossMab and deglycosylated / plasmin digested or alternatively deglycosylated / limited LysC digested CrossMab.

[0639] The VH / VL CrossMab was deglycosylated with N-glycosidase F in phosphate or Tris buffer at a protein concentration of 1 mg / ml at 37°C for up to 17 hours. Plasmin or limited LysC (Roche) digestion was performed with 100 μg of deglycosylated VH / VL CrossMab in Tris buffer pH 8 at room temperature for 120 hours and at 37°C for 40 minutes, respectively. Before mass spectrometry, the sample was desalted via HPLC on a Sephadex G25 column (GE Healthcare). The total mass was determined via ESI-MS on a maXis 4G UHR-QTOF MS system (Bruker Daltonik) equipped with a TriVersa NanoMate source (Advion).

[0640] Determine the binding and binding affinity of multispecific antibodies to corresponding antigens using surface plasmon resonance (SPR) (BIACORE)

[0641] The generated antibodies were investigated for binding to the corresponding antigens by surface plasmon resonance using a BIACORE instrument (GE Healthcare Biosciences AB, Uppsala, Sweden). In brief, for affinity measurements, goat anti-human IgG, JIR 109-005-098 antibody was immobilized on a CM5 chip via amine coupling for presentation of antibodies to the corresponding antigens. Binding was measured at 25°C (or alternatively at 37°C) in HBS buffer (HBS-P (10mM HEPES, 150mM NaCl, 0.005% Tween 20, pH 7.4)). Antigens (R&D Systems or internal purification) were added at various concentrations in solution. Binding was measured by 80 seconds to 3 minutes of antigen injection; dissociation was measured by washing the chip surface with HBS buffer for 3-10 minutes, and the KD value was estimated using a 1:1 Langmuir binding model. Negative control data (eg buffer curve) were subtracted from the sample curves to correct for system intrinsic baseline drift and noise signal reduction. Analysis of sensorgrams and calculation of affinity data were performed using the corresponding Biacore evaluation software.

[0642] Example 1

[0643] Preparation, purification and characterization of FAP-41BBL antigen-binding molecules

[0644] The FAP-targeted Fc fusion antigen binding molecule containing a 4-1BB ligand trimer was prepared as described in International Patent Application Publication No. WO 2016 / 075278 A1.

[0645] In particular, the following molecule is generated:

[0646] a) Monovalent FAP-targeted and non-targeted Fc-fusion antigen binding molecules containing 4-1BB ligand trimer

[0647] The polypeptide of the dimeric 4-1BB ligand fused with the human CL domain is subcloned in the same frame with the human IgG1 heavy chain CH2 and CH3 domains on the section (Merchant, Zhu et al., 1998, Nature Biotechnol.16, 677-681). A polypeptide containing a 4-1BB ligand outer domain is fused with the human IgG1-CH1 domain. In construct 2.4, in order to improve the correct pairing of the chain, the following mutations are additionally introduced in the cross CH-CL (charged variant). In the dimeric 4-1BB ligand fused with human CL, E123R and Q124K, in the monomeric 4-1BB ligand fused with human CH1, K147E and K213E.

[0648] DNA sequences encoding the heavy and light chain variable regions of a binder specific for FAP (clone 28H1 or clone 4B9) were subcloned in frame with either the constant heavy chain of the cave or the constant light chain of human IgG1. Pro329Gly, Leu234Ala and Leu235Ala mutations have been introduced in the constant region of the cave heavy chain to eliminate binding to the Fc gamma receptor according to the method described in WO 2012 / 130831. The combination of dimeric ligands - Fc cave chains containing S354C / T366W mutations, monomeric CH1 fusions, targeted anti-FAP - Fc cave chains containing Y349C / T366S / L368A / Y407V mutations and anti-FAP light chains allows the generation of heterodimers, which include assembled trimeric 4-1BB ligands and FAP binding Fab ( Figure 1A A non-targeted version has accordingly been prepared by replacing the FAP binder with germline DP47 ( Figure 1C ).

[0649] Table 1: Monovalent constructs

[0650]

[0651] b) Bivalent FAP-targeted and non-targeted Fc-fusion antigen binding molecules containing 4-1BB ligand trimer

[0652] The DNA sequences of the heavy and light chain variable regions encoding the FAP-specific binders (clone 28H1 or clone 4B9) were subcloned in the same frame with either the constant heavy chain of the cave, section or the constant light chain of human IgG1. Pro329Gly, Leu234Ala and Leu235Ala mutations were introduced into the constant region of the section and cave heavy chains according to the method described in WO 2012 / 130831 to eliminate binding to Fc gamma receptors. In addition, a polypeptide comprising two 4-1BB ligand outer domains was fused to the C-terminus of the human IgG1 Fc cave chain and a polypeptide comprising a 4-1BB ligand outer domain was fused to the C-terminus of the human IgG1 Fc section chain. The combination of the anti-FAP huIgG1 dimer ligand containing the heavy chain with Y349C / T366S / L368A / Y407V mutations, the anti-FAP huIgG1 monomer ligand containing the heavy chain with S354C / T366W mutations, and the anti-FAP light chain allows the generation of heterodimers, which include the assembled trimeric 4-1BB ligand and two FAP binding Fabs ( Figure 1B A non-targeted version has accordingly been prepared by replacing the FAP binder with germline DP47 ( Figure 1D ).

[0653] Table 2: Bivalent constructs

[0654]

[0655] The generation and characterization of FAP-targeted and non-targeted Fc-fusion antigen binding molecules containing 4-1BB ligand trimer are described in detail in WO 2016 / 075278, Examples 1 to 6, respectively.

[0656] Example 2

[0657] Preparation, purification and characterization of FAP-targeted mouse 4-1BBL antigen-binding molecules (hybrid surrogates)

[0658] A bispecific antigen binding molecule comprising an agonistic mouse 4-1BB ligand and a monovalent binding to FAP, also referred to as a hybrid replacement or FAP-mu4-1BBL, was prepared as described in International Patent Application Publication No. WO 2016 / 075278 A1. Targeted mouse 4-1BBL was prepared as described for the human ligand by replacing the human ligand with a mouse extracellular domain.

[0659] The DNA sequence of the partial outer domain (amino acid 104-309, including C160S mutation) of the mouse 4-1BB ligand was synthesized according to the Q3U1Z9-1 sequence of the Uniprot database. The FAP conjugate for targeting the 4-1BB ligand is clone 4B9. The amino acid sequence for the hybrid alternative FAP-mu4-1BBL can be found in Table 3.

[0660] Table 3: Amino acid sequence of the mature hybrid surrogate FAP-mu4-1BBL

[0661]

[0662]

[0663] The hybrid surrogate FAP-mu4-1BBL was generated by co-transfecting suspension-growing CHO-K1 cells with mammalian expression vectors using eviFect (Evitria AG). Cells were transfected with the corresponding expression vectors at a 1:1:1:1 ratio ("vector Fc-hole heavy chain": "vector FAP light chain": "vector 4-1BBL Fc-knob heavy chain": "vector mu4-1BBL light chain").

[0664] For transfection, CHO-K1 cells were cultured in serum-free suspension in eviMake culture medium (Evitria AG). After 7 days at 37°C in an incubator with 5% CO2 atmosphere, the culture supernatant was collected for purification by centrifugation and the solution was sterile filtered (0.22 mm filter) and stored at 4°C.

[0665] By using the affinity chromatography of protein A, the protein secreted from the cell culture supernatant is purified by size exclusion chromatography. For affinity chromatography, the supernatant is loaded on the protein A AbSelectSure column (GE Healthcare) balanced with 20mM sodium phosphate, 20mM sodium citrate, pH 7.5. Unbound protein is removed by cleaning with a buffer (pH 7.5) containing 20mM sodium phosphate, 20mM sodium citrate. The linear pH gradient of sodium chloride eluting binding using 20mM sodium citrate, 100mM NaCl, 100mM glycine, 0.01% Tween20, pH 3.0. Then 20mM sodium citrate, 100mM NaCl, 100mM glycine, 0.01% Tween20, pH 3.0 are used to clean the column. The pH of the fraction collected is adjusted by adding 1 / 40 (v / v) of 2MTris, pH 8.0. The protein was concentrated and filtered before loading on a HiLoad Superdex column (GE Healthcare) equilibrated with 20 mM histidine, 140 mM NaCl, 0.01% Tween 20, pH 6.0.

[0666] The protein concentration of the purified bispecific constructs was determined by measuring the OD at ...

Claims

1. A 4-1BB (CD137) agonist for use in a method for treating cancer or delaying cancer progression, wherein the 4-1BB (CD137) agonist is used in combination with a HER-2 targeting agent and wherein the 4-1BB agonist is an antigen binding molecule comprising at least one antigen binding domain that can specifically bind to a tumor-associated antigen.

2. The 4-1BB (CD137) agonist for use in the method of claim 1, wherein the HER-2 targeting agent comprises a HER-2 antibody, a HER-2 bispecific antibody and / or a HER-2 antibody drug conjugate.

3. The 4-1BB (CD137) agonist for use in the method of claim 1 or 2, wherein the HER-2 targeting agent comprises trastuzumab, pertuzumab, and / or trastuzumab emtansine.

4. The 4-1BB (CD137) agonist for use in a method according to any one of claims 1 to 3, wherein the 4-1BB agonist comprises three 4-1BBL extradomains or fragments thereof.

5. The 4-1BB (CD137) agonist for use in the method according to any one of claims 1 to 4, wherein the 4-1BB agonist is a molecule comprising three 4-1BBL extradomains or fragments thereof and wherein the 4-1BBL extradomains comprise an amino acid sequence selected from the group consisting of SEQ ID NO: 1, SEQ ID NO: 2, SEQ ID NO: 3, SEQ ID NO: 4, SEQ ID NO: 5, SEQ ID NO: 6, SEQ ID NO: 7 and SEQ ID NO: 8, in particular an amino acid sequence of SEQ ID NO: 1 or SEQ ID NO:

5.

6. A 4-1BB (CD137) agonist for use in a method according to any one of claims 1 to 5, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to a tumor-associated antigen selected from the group consisting of fibroblast activation protein (FAP) and CEA.

7. The 4-1BB (CD137) agonist for use in the method according to any one of claims 1 to 6, wherein the 4-1BB agonist is an antigen binding molecule comprising an IgG Fc domain, specifically an IgG1 Fc domain or an IgG4 Fc domain.

8. The 4-1BB (CD137) agonist for use in the method of any one of claims 1 to 7, wherein the 4-1BB agonist is an antigen binding molecule comprising an Fc domain comprising one or more amino acid substitutions that reduce binding to an Fc receptor and / or effector function.

9. The 4-1BB (CD137) agonist for use in the method of any one of claims 1 to 8, wherein the 4-1BB agonist is an antigen binding molecule comprising three 4-1BBL ectodomains or fragments thereof and at least one antigen binding domain capable of specifically binding to fibroblast activation protein (FAP).

10. The 4-1BB (CD137) agonist for use in the method according to any one of claims 1 to 9, wherein the antigen binding domain capable of specifically binding to a tumor-associated antigen is an antigen binding domain capable of specifically binding to FAP, and the antigen binding domain capable of specifically binding to FAP comprises (a) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 9, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 10, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 11, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 12, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 13, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 14, or (b) Heavy chain variable region (V H FAP and light chain variable region (V L FAP), the heavy chain variable region (V H FAP) comprises (i) a CDR-H1 comprising the amino acid sequence of SEQ ID NO: 15, (ii) a CDR-H2 comprising the amino acid sequence of SEQ ID NO: 16, and (iii) a CDR-H3 comprising the amino acid sequence of SEQ ID NO: 17, the light chain variable region (V L FAP) comprises (iv) a CDR-L1 comprising the amino acid sequence of SEQ ID NO: 18, (v) a CDR-L2 comprising the amino acid sequence of SEQ ID NO: 19, and (vi) a CDR-L3 comprising the amino acid sequence of SEQ ID NO: 20.